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Abstract
Context: There is increasing evidence that Vitamin D (Vit D) and its metabolites, besides their
well-known calcium-related functions, may also exert antiproliferative, pro-differentiating, and
immune modulatory effects on tumor cells in vitro and may also delay tumor growth in vivo.
Objective: The aim of this review is to provide fresh insight into the most recent advances on the
role of Vit D and its analogues as chemopreventive drugs in cancer therapy.
Methods: A systematic review of experimental and clinical studies on Vit D and cancer was
undertaken by using the major electronic health database including ISI Web of Science,
Medline, PubMed, Scopus and Google Scholar.
Results and conclusion: Experimental and clinical observations suggest that Vit D and its
analogues may be effective in preventing the malignant transformation and/or the progression
of various types of human tumors including breast cancer, prostate cancer, colorectal cancer,
and some hematological malignances. These findings suggest the possibility of the clinical use
of these molecules as novel potential chemopreventive and anticancer agents.
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Introduction
The clinical use of cytotoxic drugs has had a significant
impact on neoplastic diseases. However, their therapeutic
effectiveness is limited due to their narrow therapeutic index
and the onset of chemoresistance. Therefore, many efforts are
currently being directed to finding new therapeutic options
that may overcome these problems. In this scenario,
chemoprevention, i.e., the use of natural, synthetic, or
biological substances to reverse, suppress, or prevent the
development and progression of malignant diseases, holds
great promise (Davis & Wu, 2012). In this context, a
consistent body of investigation provides evidence that
Vitamin D (Vit D) and its metabolites, in addition to its
well-known involvement in calcium homeostasis, also appears
to be effective in preventing the malignant transformation and
the progression of various types of human tumors (Krishnan
& Feldman, 2010; Nagpal et al., 2005; Vuolo et al., 2012). On
one hand, experimental evidence indicates that these effects
appear to be likely due to the antiproliferative, proapoptotic,
and immunomodulatory activities with which these molecules
are endowed (Krishnan & Feldman, 2010; Vanoirbeek et al.,
2011). On the other hand, numerous epidemiological obser-
vations based on geographic variation in the incidence of
cancer and\or mortality in relation to 18 different types of
human cancer clearly demonstrate that Vit D exerts
chemopreventive effects on at least three types of solid
tumors at high risk of mortality, namely breast cancer
(Khan et al., 2010), prostate cancer (Swami et al., 2011),
and colorectal cancer (Pereira et al., 2012) and on squamous
cell carcinoma (SCC) and some hematological malignances
(Kim et al., 2012; Reddy, 2013). The aim of this paper is to
provide insight into the most recent advances on the role of
Vit D as chemopreventive drug in cancer therapy.
Vit D chemical structure, biological functions, and
metabolism
The Vit D complex includes a group of fat-soluble pro-
hormones that contribute to maintaining calcium and phos-
phate homeostasis and bone and muscle integrity (Bouillon
et al., 2008). On one hand, Vit D is known to be essential for
the absorption of calcium and phosphate ions in the small
intestine, their mobilization from the bone tissue, and their
resorption in the kidney (Bouillon et al., 2008). These effects
suggest an indirect involvement of this molecule in the
regulation of the normal function of different tissues such as
muscle contraction, nerve conduction, bone metabolism, and
blood clotting (Bouillon et al., 2008). Interestingly, emerging
evidence suggests that Vit D also appears to be implicated in
the regulation of other important biological processes such as
cell proliferation and differentiation (Gocek & Studzinski,
2009), immune response (Hewison, 2011), and insulin
secretion (Teegarden & Donkin, 2009). Vit D is available in
two main distinct forms: i.e., Vitamin D2 (Vit D2)
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(ergocalciferol) and Vitamin D3 (Vit D3) (cholecalciferol)
(Figure 1). Vit D2 is synthesized in plants, yeasts, and fungi
whereas Vit D3 is of animal origin (Bouillon et al., 2008;
Ja¨pelt & Jakobsen, 2013) (Figure 1). Vit D2 is derived from
ergosterol, which is turned into viosterol by ultraviolet (UV)
light and then converted into ergocalciferol. In this form, Vit
D2 can be ingested from the diet and from supplements
(Figure 1). On the other hand, the exposure of skin to
ultraviolet B radiation (UVB; 290–320 nm) converts 7-
dehydrocholesterol (DHCR7) to pre-vitamin D3 (1,25-dihy-
droxycholecalciferol or calcitriol) which isomerizes to Vit D3
(Figure 1) (Bouillon et al., 2008; Ja¨pelt & Jakobsen, 2013). In
this form, Vit D3 binds to Vit D-binding protein (DBP) and is
then transported into the liver. Vit D complex molecules are
known as secosteroids, namely steroids in which one of the
rings of its cyclopentanoperhydrophenanthrene structure has a
broken carbon–carbon bond. Vit D2 and Vit D3 differ in their
side chains in that the side chain of the D2 form additionally
contains a double bond between carbons 22 and 23 and a
methyl group on carbon 24 (Figure 1). The biosynthetic
pathway of Vit D3 involves the hepatic hydroxylation of the
carbon atom in position 25 by four cytochrome P450
isoenzymes, i.e., CYP2R1, CYP2J2, and CYP3A4 isoforms
and the mitochondrial CYP27A1 isoform (Figure 1) (Jones
et al., 2014; Schuster, 2011). This first hydroxylation
generates the main circulating form of Vit D, namely 25-
hydroxyvitamin D3 [25(OH)D] or calcidiol (Figure 1).
Normal serum values of 25(OH)D are comprised between
25 and 130 nmol/L depending on the geographic location
(Ross et al., 2011). This form reflects dietary sources as well
as Vit D production by UV light on the skin (Ross et al.,
2011). A second hydroxylation in the 1-a position occurs in
the kidney, at the tubule proximale levels, where it leads to the
formation of 1a,25(OH)2D3 (calcitriol) which is the most
biologically active form of Vit D (Figure 1) (Jones et al.,
2014; Schuster, 2011). Once synthesized in the kidney, via
CYP27B1 (25-hydroxyvitamin D3 1-a-hydroxylase), this
active form enters the bloodstream and it is then transported,
by specific binding proteins (VDBP) to distant target tissues
(Bouillon et al., 2008) (Figure 1). Vit D activity is tightly
regulated by metabolic processes mediated by the CYP24A1
isoform (1,25-dihydroxyvitamin D3 24-hydroxylase) that
converts 1a,25(OH)2D3 into 1,24,25-trihydroxycholecalci-
ferol [1a,24,25(OH)3D3] which has a lower affinity for Vit
Figure 1. Synthesis and metabolism of secosteroids Vitamin D3 and Vitamin D2. In humans, cholecalciferol (Vitamin D3) is synthesized from 7-
dehydrocholesterol upon sunlight exposure. Vitamin D may also be obtained from dietary sources or supplements as ergocalciferol or Vitamin D2.
Vitamin D3 binds to Vitamin D-binding protein (DBP) in the bloodstream and then is transported to the liver where it is first converted by the enzyme
25-hydroxylase (CYP2R1) to 25-hydroxyvitamin D [25(OH)D]. This molecule is converted by the renal enzyme 1-a hydroxylase (CYP27B1) to 1,25
dihydroxycholecalciferol (calcitriol), which is the active form of Vitamin D. The rate limiting step in catabolism is the degradation of 25(OH)D3 and
1,25(OH)2D3 to 24,25(OH)D3 and 1,24,25(OH)2D3, respectively, which occurs through 24-hydroxylation by mitochondrial 1,25-dihydroxyvitamin D3
24-hydroxylase, (CYP24A1). 24,25(OH)D3 and 1,24,25(OH)2D3 are excreted in this form.
2 M. Giammanco et al. Pharm Biol, Early Online: 1–36
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D receptors (VDR) (Schuster, 2011). This molecule, then,
undergoes a further metabolization to generate calcitroic acid
which is excreted in this form (Figure 1). In contrast,
expression levels of renal 1-a hydroxylase (CYP27B1),
namely the enzyme which converts 1,25-hydroxycholecalci-
ferol into 1,25-dihydroxycholecalciferol, are positively regu-
lated by high calcium and phosphate levels parathyroid
hormone (PTH), calcitonin, growth hormone, and insulin-like
growth factor-I (IGF-I) (Henry, 2011). Conversely, low
calcium and phosphate levels, fibroblast growth factor 23
(FGF23), and 1,25(OH)2D3 itself function as negative regu-
lators of this enzyme (Fukumoto, 2014). However, PTH and
1a,25(OH)2D3 have no effect on the expression and/or
activity of extrarenal 1a-hydroxylase. Other rate-limiting
steps in Vit D metabolism involve the modulation of CYP2R1
(Vit D 25-hydroxylase) activity, which is induced by
decreased level of 25(OH)D and that of CYP24A1 which is
induced by 25(OH)D and 1,25(OH)2D3 (Bouillon et al., 2008;
Schuster, 2011).
Vit D receptor: structure and functions
The biological effects induced by the active form of Vit D and
its semisynthetic analogues are mediated by the vitamin D
receptor (VDR), also known as NR1I1 receptor (Wang et al.,
2012). This receptor belongs to the superfamily of the nuclear
receptor (NR) that includes receptors for steroid hormone,
retinoids, and thyroid hormones. VDR is located in the
nucleus of a variety of target cells including cells of the
immune system (Wang et al., 2012). Similar to other nuclear
receptors, VDR shows a domain structure which is homolo-
gous to that of these receptors (Bouillon et al., 2008; Haussler
et al., 2011). This domain can be functionally divided into
three regions with well-characterized functions, i.e., (a) an
aminoterminal region factor that binds a short N-terminal
activation-function 1 (AF-1) domain (A/B) and that plays an
important role in the VDR-mediated transactivation; (b) a
central region that contains a DNA-binding domain (DBD)
which interacts directly with the cellular DNA at the level of
Vit D-response elements (VDREs). This region contains two
Zn2+-finger (C) portions consisting of four cysteine residues
that coordinate a zinc atom; (c) a carboxy-terminal region that
encompasses a multifunctional domain named ligand-binding
domain (LBD), which may interact with different ligands such
as retinoid X receptor (RXR) and the transcriptional regula-
tory factor AF-2 (Bouillon et al., 2008).
Vit D and regulation of gene expression
The effects induced by Vit D may occur in three different
ways through the modulation of the expression of specific
genes responsive to Vit D (Haussler et al., 2011, 2013;
Kriebitzsch et al., 2009). In particular, the transcription of
genes that are involved in the regulation of bone-remodeling
processes, such as receptor activator of NF-kB ligand
(RANKL), carbonic anydrase II, osteocalcin, osteopontin,
or other genes, such as phospholipase C (PLP C),
24-hydroxylase or CYP3A4, b3 integrin, tumor suppressor
p21, insulin growth factor-binding protein-3 (IGFB-3), can be
positively regulated by a direct interaction with vitamin D
response elements (VDREs) present in their promoter regions
(Cao et al., 1993; Haussler et al., 2011, 2013). Conversely, Vit
D, through the interaction with negative VDREs, may
negatively regulate the expression of gene encoding for
several pro-inflammatory cytokines such as interleukin-2 (IL-
2) and interleukin-12 (IL-12), tumor necrosis factor a (TNF-
a), interferon g (IFN-g), and/or growth factors and receptors
such as epidermal growth factor receptor (EGFR), c-myc, and
hormones involved in calcium homeostasis including para-
thyroid hormone (PTH), parathyroid hormone-related peptide
(PTHrP), and rel-B (Haussler et al., 2011, 2013). Gene
transcription may also be inhibited by the expression of genes
that antagonize the effects of specific transcription factors,
such as (NF)-aT and NF-kB (Haussler et al., 2013).
Vit D signal transduction pathways
To date, two major signal transduction pathways activated by
Vit D in target cells have been identified, namely the so-called
‘‘genomic pathway,’’ where the Vit D nuclear receptor plays a
major role, and the ‘‘non-genomic signal transduction path-
way’’ (Haussler et al., 2011). This latter pathway triggers
those responses mediated by Vit D that are faster than those
induced following changes in gene expression. In this case,
Vit D is supposed to interact directly with a receptor present
in the plasma membrane (mVDR). This interaction induces
rapid changes in intracellular calcium concentrations, alter-
ations in membrane phospholipid metabolism, and activation
of several signaling transduction pathways (Haussler et al.,
2011). In order to ensure the full biological activity of
1,25(OH)2D3 both pathways needed to be activated.
Following the binding of 1,25(OH)2D3 to VDR, the receptor
is phosphorylated. In this form, VDR may promote the
recruitment of its preferred dimerization partner, namely the
nuclear receptor for 9-cis retinoic acid (RXR), thus forming a
heterodimer that, in turn, binds to VDR responsive elements
(VDREs) (Haussler et al., 2011). In the absence of its ligand,
most of the Vit D receptors are located in the cytoplasm.
However, upon interaction with 1,25(OH)2D3 and the subse-
quent heterodimerization the complex migrates from the
cytoplasm into the nucleus. The 1,25(OH)2D3-VDR–RXR
complex then interacts with DNA at VDREs level that is
located in the classic promoter regions of responsive genes,
near the transcription start site of the gene (Haussler et al.,
2011, 2013). Downstream targets of these genes are
implicated in mineral metabolism and in the regulation of
other metabolic pathways including those involved in the
immune response and cancer.
Effects of vitamin D on tumor progression
The prophylactic and therapeutic activities of Vit D toward
the most common types of cancer have been extensively
investigated either in vitro or in vivo (Khan et al., 2010;
Leyssens et al., 2013; Pereira et al., 2012; Swami et al., 2011).
The most striking results have been obtained following studies
on breast cancer, prostate cancer, and colorectal cancer
(Krishnan & Feldman, 2010; Leyssens et al., 2013;
McCulloug et al., 2009). Experimental observations suggest
that the chemopreventive effects of Vit D appear to be mainly
due to its modulating activity on important biological
functions such as cell proliferation, cell differentiation,
DOI: 10.3109/13880209.2014.988274 Vitamin D and cancer 3
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growth factors gene expression, signal transduction, and
apoptosis (Gocek & Studzinski, 2009; Haussler et al., 2013;
Samuel & Sitrin, 2008) (Table 1). The inhibiting effects of Vit
D on tumor cell growth were first described by Colston et al.
(1981) who showed for the first time a dose-dependent
decrease of cell proliferation in melanoma cells treated with
1,25(OH)2D3. The growth inhibiting activity of this molecule
was subsequently observed in other tumor cell lines including
breast, prostate, and colon cancer cells (Welsh, 2012). These
studies also highlighted the presence of specific receptors
with high affinity for 1,25(OH)2D3 that appeared to be
essential for the growth inhibitory activity exerted by Vit D
(Welsh, 2012). In line with these observations, other in vitro
studied reported that antisense oligonucleotides, which
decreased the intracellular levels of VDR, reduced the
sensitivity of tumor cells to the antiproliferative effects of
1,25(OH)2D3 (Hedlund et al., 1996; Welsh, 2012). On the
contrary, VDR overexpression resulted in a potentiation of
cell growth arrest (Hedlund et al., 1996; Welsh, 2012; Zhuang
et al., 1997). Interestingly, recent studies have shown that
1,25(OH)2D3 may also affect ovarian cancer cells prolifer-
ation by decreasing human telomerase reverse transcriptase
(hTERT) mRNA through a small non-coding RNA (Ikeda
et al., 2003; Kasiappan et al., 2012). Consistent with these
observations a recent experimental investigation has shown
that, in ovarian tumor and ovarian cancer cell lines,
microRNA-498 (miR-498) induced by 1,25OH2D3 decreased
hTERT mRNA expression, fostered cell death, and sup-
pressed tumor growth (Kasiappan et al., 2012). Conversely,
the ability of 1,25OH2D3 to decrease hTERT mRNA and to
suppress ovarian cancer growth was compromised in the
absence of miR-498, following its depletion in cell lines and
in tumor-bearing mice (Kasiappan et al., 2012). Finally, Vit D
has been reported to foster several types of malignant cells
to undergo differentiation toward more mature phenotypes
or to induce cell death by triggering apoptosis according to
the cell type (Gocek & Studzinski, 2009).
Effects of Vit D on cyclin/cycline-dependent kinase
system
Many investigations undertaken with the aim of assessing a
direct effect of 1,25OH2D3 on the expression levels of genes
encoding for intracellular inhibitors of the cell cycle demon-
strate that this molecule may increase the expression of
cyclin-dependent protein kinase (CDK) inhibitors p21 and
p27, while it decreases the expression of cycline regulatory
proteins such as cyclin-dependent kinase 2 (Cdk2) (Colston &
Hansen, 2002; Hager et al., 2001; Wang et al., 1996; Yang &
Burnstein, 2003). These phenomena ultimately lead to a
growth arrest of cells in the G0/G1 phase. In addition, Vit D
has been shown to inhibit human breast cancer and prostate
cancer cell-cycle progression by blocking cells in G1/S
transition (Istfan et al., 2007; Jensen et al., 2001). This effect
appears to be due to the conversion of the retinoblastoma gene
(Rb), which is a direct target of cyclin-CDK complexes, in its
active hypophosphorylated form (Jensen et al., 2001).
Furthermore, other in vitro studies on SCC cells show that a
30 h exposure of these cells to 1,25(OH)2D3 induces the
overexpression of p18 tumor suppressor gene but not that of
p27 or p19 gene, which regulates G1 progression, by forming
a stable complex with CDK4 or CDK6 and by preventing the
activation of CDK kinases (Gedlicka et al., 2006). However,
in LNCaP human prostate cancer cell line, 1,25(OH)2D3
induces a marked increase of p21 gene while, in RWPE-1
prostate epithelial cells, VDR may epigenetically regulate p21
gene expression by generating histone modifications in the
promoter (Flores et al., 2010). Moreover, 1,25(OH)2D3 may
also regulate p21 expression levels by modulating miR-106b
expression (Thorne et al., 2011). Conversely, in MCF-7
human breast cancer cells 1,25(OH)2D3 show minimal effects
on the expression levels of mRNA coding for p21 (Verlinden
et al., 1998). These findings suggest that, according to the cell
types, the growth inhibitory effect of 1,25(OH)2D3 does not
appear to be related to an activation of VDR- mediated p21
gene transcription. In contrast, Swami et al. (2003) high-
lighted the fact that, in MCF-7 MDA-MB-231 estrogen
receptor a positive [ERa(+)] and estrogen receptor a negative
[ER a()] human breast cancer cells, the treatment with
1,25(OH)2D3 induces different profiles of gene expression
with a few overlapping genes. These findings further support
the hypothesis that different cellular pathways regulated by
1,25(OH)2D3 may be involved in the growth inhibitory effects
in different tumor cells.
Vit D-mediated regulation of the forkhead box O
(FoxO) proteins
The forkhead box O (FoxO) proteins belong to a family of
transcription factors that plays an important role in tumor
suppression by upregulating target genes involved in cell-
cycle arrest and apoptosis (An et al., 2010). In particular,
FoxO1 (FKHR), FoxO3A (FKHRL1), FoxO4 (AFX), and
FoxO6 regulate cell proliferation and differentiation. They are
inhibited by phosphatidylinositol-3-kinase (PI3K), which
stimulates their Akt-dependent phosphorylation and nuclear
export. The biological functions of several members of the
FoxO family are inhibited by phosphorylation induced by
mitogen-activated protein kinases (MAPKs) such as ERK and
p38. Interestingly, recent findings show that the interaction
between 1,25(OH)2D3 and VDR induces post-translational
modifications and functional alterations of FoxO proteins (An
et al., 2010). In fact, in vitro studies report that the treatment
of human head and neck SCC (HNSCC) with 1,25(OH)2D3
potentiates the binding of FoxO3A and FoxO4 proteins to
FoxO promoter target genes and causes a block in the
mitogen-induced FoxO protein nuclear export (An et al.,
2010). Furthermore, in vitro investigations on human neuro-
blastoma cells show that a 4 h exposure of these cells to
1,25(OH)2D3 induces the deacetylation and the dephosphor-
ylation of FoxO. Consistent with these observations, the arrest
of cell-cycle progression induced by Vit D is not observed in
cells lacking FoxO3 and FoxO4 (An et al., 2010). These
findings further indicate that FoxO proteins appear to play a
key role as mediators of the anti-proliferative effects of Vit D
in some human tumors.
Insulin growth factor modulation by Vit D
Experimental evidence shows that Vit D may also negatively
affect cell proliferation by interfering with several growth
4 M. Giammanco et al. Pharm Biol, Early Online: 1–36
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factors. In particular, Vit D appears to be implicated in the
regulation of insulin growth factor (IGF) and in that of certain
IGF-binding proteins including the major binding protein
IGFBP-3 (Boyle et al., 2001; Matilainen et al., 2005; Peng
et al., 2004; Teegarden & Donkin, 2009). These observations
are in line with the results from in vitro studies on MCF-7 and
Hs578T human breast cancer cell lines showing that two
Vit D analogues EB1089 and CB1093 may inhibit the
stimulating effects of IGF-I on cell growth and may enhance
the production of IGFBP-3 which, in turn, regulates the
promoting activity of IGF-I and IGF-II on cell proliferation
(Colston et al., 1998). Similar effects were observed in
prostate cancer cells following their exposure to Vit D or its
analogues (Huynh et al., 1998; Sprenger et al., 2001). The
role of IGFBP-3 as a critical mediator of the antiproliferative
activity of Vit D has been further highlighted by other studies
which show that antisense oligonucleotides against IGFBP-3
antagonize the growth-inhibiting effects of Vit D in androgen-
responsive LNCaP human prostate cancer cells (Boyle et al.,
2001; Krishnan et al., 2004). On one hand, in agreement with
these data, Peng et al. (2008) have recently shown that, in the
LNCaP human prostate cancer cell line, high concentrations
of androgens exert growth inhibitory effects at least partially
through the IGFBP-3-p21/p27 pathway. On the other hand,
in vivo studies by Nickerson and Huynh (1999) show that the
administration of Vit D analog EB1089 to rats for 14 d
increases the expression of several isoforms of IGFBPs,
including IGFBP-3, in the prostatic tissue and that these
effects were associated with a reduction of prostate volume.
As IGFBP-3 has been shown to possess pro-apoptotic,
antimetastatic, and anti-angiogenic activities against prostate
cancer cells (Massoner et al., 2009), it is conceivable to
hypothesize that the modulation of IGFP-3 expression by Vit
D may be a possible effective therapeutic option in the
clinical treatment of prostate cancer.
Transforming growth factor-b modulation by Vit D
Transforming growth factor-b (TGF-b) is a member of growth
factor of the namesake superfamily of growth factors which is
implicated in the regulation of several important biological
processes such as cell proliferation, differentiation, motility,
adhesion, organization, and programmed cell death
(Massague´, 2008). TGF-b is known to inhibit the proliferation
of normal epithelial cells and the early steps of carcinogenesis
while it fosters the later steps of cancer progression, e.g., cell
motility, invasion, and metastasis (Massague´, 2008). Vit D
and TGF-b share similar effects on cell growth and differen-
tiation (Daniel et al., 2007; Wu et al., 1998). Experimental
studies stress that, according to the cell type, Vit D may
increase the expression levels of TGF-b and that of its
receptors (Chen et al., 2002; Daniel et al., 2007; Koli &
Keski-Oja, 1995; Tu et al., 2013; Wu et al., 1997a,b, 1998;
Yanagisawa al., 1999) or its secretion (Bizzarri et al., 2003;
Koli & Keski-Oja, 1995). These effects, which may in part,
account for the anti-proliferative effects of Vit D, were also
described as occurring in various breast cancer cell lines such
as MCF-7, MDA-MB-231, or MCF10CA (Lee et al., 2006;
Swami et al., 2003; Wu et al., 1998; Yang et al., 2001) and in
prostate cancer cells (Murthy & Weigel, 2004; Peehl et al.,
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2004). In particular, some of these studies show that short-
term exposure (512 h) to 1,25(OH)2D3 or to its analog
EB1089 results in an increased expression level of TGF-b
and/or TGF-b receptors in breast cancer cells (Yang et al.,
2001). In addition, other in vitro observations on LNCaP
prostate cancer cells show that the growth-inhibiting effects of
1,25(OH)2D3 on these tumor cells appear to be associated
with the increased expression and secretion of the growth
differentiation factor-15 (GDF-15), another member of the
TGF-b superfamily of growth factors (Lambert et al., 2006).
Interestingly, the effects of a long-term treatment with
1,25(OH)2D3 on the mRNA levels encoding different mem-
bers of the family TGF-b are also reported on other tumor cell
types such as colorectal cancer cells or squamous carcinoma
cells (Lin et al., 2002; Pa´lmer et al., 2003).
Vit D interaction with Wnt/b-catenin-signaling
pathways
Another possible mechanism by which Vit D may halt cell
proliferation involves the inhibition of some of the numerous
functions mediated by the Wnt/b-catenin-signaling pathway.
To this end, in vitro observations show that in colon cancer
cell lines 1,25(OH)2D3 can block the transcriptional regula-
tion mediated by b-catenin by decreasing the formation of the
transcriptional complex TCF4-b-catenin (Larriba et al.,
2013). Consistent with this hypothesis, Xu et al. (2010)
have demonstrated that administration of 1,25(OH)2D3 or that
of its analogues for 12 weeks reduces the number of polyps in
the colon mucosa and that, in the small intestine and in the
colon, this effect is associated with a reduced expression of
target genes for b-catenin. The effects mediated by Vit D may
also indirectly affect the function of b-catenin through an
increased production of E-cadherin, a membrane protein that
binds b-catenin, thus preventing its nuclear localization and
transactivation (Pa´lmer et al., 2001). However, there is
evidence that 1,25(OH)2D3 may also inhibit the growth of
many different cells without affecting cadherin expression.
These findings indicate that the up-regulation of E-cadherin is
just one of the mechanisms by which Vit D may negatively
affect the b-catenin signaling pathway (Shah et al., 2006).
These observations also indicate that the effects of
1,25(OH)2D3 on the growth and differentiation of many
different epithelial cancer cells may be, in part, explained by
its ability to differentially regulate the activity of VDR, E-
cadherin, and b-catenin/TCF pathways (Beildeck et al., 2009;
Shah et al., 2006). 1,25(OH)2D3 may also interact with the
Wnt/b-catenin-signaling pathway by affecting the expression
of Wnt regulators, for instance, by up-regulating the expres-
sion of the Wnt antagonist Dickkopf-1 (DKK-1) protein
(Penda´s-Franco et al., 2008b). However, whether all the DNA
binding sites for b-catenin are equally inhibited by VDR and
whether the link of b-catenin in different sites is equally
influenced by 1,25(OH)2D3 and VDR remain still unraveled.
Further studies may better define these interactions.
Vit D and apoptosis
The induction of apoptosis is an additional, important mech-
anism by which Vit D appears to exert its chemopreventive
effects on cancer cell growth (Vanoirbeek et al., 2011).
Vit D has been shown to promote apoptosis in breast cancer,
prostate cancer, colon cancer, and SCC cells (Gocek &
Studzinski, 2009). However, this phenomenon is not univocal.
For instance, Zhang et al. (2005) have reported that, in
ovarian cancer cells, Vit D may inhibit apoptosis. These
findings are in agreement with the results of several studies
showing that Vit D may positively or negatively modulate the
expression of anti-apoptotic or pro-apoptotic factors accord-
ing to the cell type (Dı´az et al., 2000; Pereira et al., 2012).
Although the mechanisms by which Vit D may promote
apoptosis remain to be fully clarified, experimental evidence
highlights the fact that 1,25(OH)2D3 can trigger the intrinsic
pathway of programmed cell death 1,25(OH)2D3 (Guzey
et al., 2002). In this context, in vitro studies on colorectal
cancer cells show that 1,25(OH)2D3 and its analogue EB1089
may promote apoptosis by a p53-independent mechanism
(Dı´az et al., 2000). These investigations also show that these
molecules may inhibit apoptosis by down-regulating the
expression of anti-apoptotic and pro-survival proteins such as
Bcl-2, Bcl-XL, or by increasing the expression of pro-
apoptotic proteins such as Bax, Bak, and Bad (Dı´az et al.,
2000). Additionally, these studies also show that the increased
expression of Bak and the reduced expression of BCl-2 in
response to EB1089 were more marked compared with that
induced by 1,25(OH)2D3 (Dı´az et al., 2000). In line with these
findings, Blutt et al. (2000) demonstrate that continuous 6-d
exposure of LNCaP cells to 1,25(OH)2D3 induces apoptosis
and that this phenomenon was associated with the down-
regulation of anti-apoptotic proteins Bcl-2 and Bcl-XL and
with the up-regulation of pro-apoptotic protein Bax. More
recently, Pan et al. (2010) have shown that 1,25(OH)2D3 may
promote apoptosis also in the HCG-27 gastric cancer cell line.
This effect appears to be the result of the up-regulation of
PTEN, a tumor suppressor gene that negatively regulates the
anti-apoptotic activity of protein kinase B (Akt), mediated
by VDR. Furthermore, in the MCF-7 cell line, the treatment
with 1,25(OH)2D3 induced an increase in the level of the
pro-apoptotic Death Associated Protein-3 (DAP-3), Fas-
Associated Death Domain (FADD), and the caspases-3, -4,
-6, and -8 (Swami et al., 2003). Consistent with these
observations in vitro studies on squamous cell carcinoma
SCC25 cells and colon cancer SW480-ADH cells show that
Vit D may potentiate its pro-apoptotic effects by increasing
the gene expression of the pro-apoptotic protein G0–G1
switch 2 (G0S2) (Pa´lmer et al., 2003) or by activating caspase
effector molecules (Pa´lmer et al., 2001). Furthermore, more
recent in vitro studies from Sergeev (2012) suggest that, in
breast cancer cells, Vit D can act as an apoptotic initiator that
directly recruits Ca(2+)-dependent apoptotic effectors such as
Ca(2+)-dependent m-calpain and Ca(2+)/calpain-dependent
caspase-12 which are capable of executing apoptosis.
Finally, Kasiappan et al. (2012) have recently reported that,
in OVCAR3 ovarian cancer cells, 1,25(OH)2D3 destabilizes
telomerase reverse transcriptase (TERT) mRNA, inducing
apoptosis through telomere attrition and the down-regulation
of telomerase activity. The multiple mechanisms underlying
Vit D-mediated apoptosis observed in different tumor cell
lines may be, in part, explained by the need for tumor cells to
develop different mechanisms that may be useful for escaping
the pro-apoptotic effects induced by Vit D.
8 M. Giammanco et al. Pharm Biol, Early Online: 1–36
D
ow
nl
oa
de
d 
by
 [G
ae
tan
o L
eto
] a
t 0
3:0
4 2
4 M
ay
 20
15
 
Vit D and autophagy
Autophagy or autophagocytosis is a catabolic process by
which cells may degrade cytosolic macromolecules and
intracellular components through the lysosomal machinery
(Singletary & Milner, 2008). This process plays a key role in
the regulation of several important biological processes such
as cell growth, development, and homeostasis, by maintaining
a balance among the synthesis, degradation, and subsequent
recycling of cellular products. Although autophagy is gener-
ally regarded as a survival strategy or a mechanism that
protects cells from stressful situations such in the case of lack
of energy reserves or oxidative stress, it can also be modulated
to determine the death of cancerous cells (Singletary &
Milner, 2008). Therefore, unlike apoptosis, autophagy, in
response to stressful stimuli, can contribute either to cell
survival or to cell death (Morselli et al., 2009; Singletary &
Milner, 2008). Many food components such as selenium,
resveratrol, curcumin, and Vit D itself have been reported to
promote autophagy (Singletary & Milner, 2008; Wu & Sun,
2011). The first evidence regarding the permissive effect of
1,25(OH)2D3 on autophagy was reported by Mathiasen et al.
(1999). These authors showed that 1,25(OH)2D3 and two
analogues EB1089 and CB1093 induced growth arrest in
MCF-7 breast cancer cells expressing the tumor suppressor
gene p53 and in T47D breast cancer cell lines line lacking
p53. Surprisingly, the same studies also highlighted the fact
that the growth-inhibiting effects of Vit D and its analogues
were also caspase independent and that the overexpression of
the anti-apoptotic protein Bcl-2, completely protected tumor
cells from autophagy induced by these molecules (Mathiasen
et al., 1999). Consistent with these data, other in vitro studies
reported that Vit D analog EB1089 induced tumor cell death
by a mechanism not related to caspase activation and which
consisted in the induction of chromatin condensation and
DNA fragmentation (Høyer-Hansen et al., 2005). In particu-
lar, these investigations showed that, in MCF-7S1 tumor cells,
autophagic activity could be increased by protein Beclin-1,
also known as autophagy-related gene ATG6. Beclin-1 is a
Bcl-2-interacting protein that promotes, in association with its
binding partner class III phosphoinositide 3-kinase (PI3K),
autophagosome formation (Høyer-Hansen et al., 2010). It may
also function as a brake for autophagy and autophagic cell
death when associated with Bcl-2 (Høyer-Hansen et al.,
2010). Conversely, this phenomenon was inhibited by the
mammalian target of rapamycin protein (mTOR) (Høyer-
Hansen et al., 2007). These findings are consistent with those
of Wang et al. (2008) showing that, in HL-60 human myeloid
leukemia cells, Vit D triggered autophagy by up-regulating
Beclin-1 and by down-regulating mTOR levels. Furthermore,
additional evidence showed that Vit D-induced autophagy
may be mediated by CDK inhibitors. For instance, Tavera-
Mendoza et al. (2006) showed that 1,25(OH)2D3 contribute to
make SCC25 cells knocked down for p19(INK4D) gene
expression more susceptible to cell death by autophagy as this
gene protects cells from autophagy-induced death (Høyer-
Hansen et al., 2005). This effect was also noted in MCF-7
human breast cancer cells (Høyer-Hansen et al., 2005).
However, 1,25(OH)2D3 has been shown to decrease the
circulating levels of TNF-a, a phenomenon that may lead to a
decreased autophagic activity induced by this molecule
(Stubbs et al., 2010). In addition, Vit D may also inhibit the
release of IFN-g from macrophages and peripheral blood
mononuclear cells (Wu & Sun, 2011). This effect may result
in an inhibition of IFN-g induced activation and potentiation
of lysosomal activity of macrophages, recruitment of
autophagic proteins and, ultimately, may lead to a decrease
of autophagy (Wu & Sun, 2011). Another possible target for
the chemopreventive activity of Vit D on cancer progression
is the nuclear factor kappa B (NF-kB), a nuclear transcription
factor involved in the regulation of many genes implicated in
inflammation, growth regulation, apoptosis, autophagy, car-
cinogenesis, and malignant progression (Aggarwal, 2004;
Baldwin, 2012). In this context, Tse et al. (2010) reported that
Vit D3 inhibited NF-kB activity in human breast cancer cells.
Likewise, a similar effect was observed by other authors on
colorectal cancer cells (Schwab et al., 2007) and prostate
cancer cells (Krishnan & Feldman, 2010). Nevertheless, as
opposing results have been also reported on the effects of Vit
D on NF-kB expression levels (Bao et al., 2010; Janjetovic
et al., 2011; Krishnan et al., 2007) further studies may better
define the role of NF-kB in autophagy and, consequently, the
potential therapeutic impact of Vit D in modulating this
phenomenon in cancer cells.
Vit D and cell differentiation
Experimental studies show that Vit D may also induce
differentiation in normal and neoplastic cells which, in some
case, may be associated with a reduced proliferation rate
(Gocek & Studzinski, 2009). The differentiating activity of
Vit D is associated with the increased expression and/or
activation of several intracellular signaling pathways. This
may, in part explain, why the mechanisms underlying Vit D-
induced differentiation may somehow differ according to the
cell types (Gocek & Studzinski, 2009). For instance Geng
et al. (2011) showed that CYP27B1/1a-hydroxylase is
required for osteoblast differentiation of human marrow
stromal cells. Recent studies suggest that the anti-apoptotic
effects of 1,25(OH)2D3 on osteoblasts and osteocytes are
mediated by Src, PI3K, and JNK kinases (Gocek &
Studzinski, 2009). The association of VDR with other
proteins appears to be important in Vit D-induced osteoblast
differentiation (Gocek & Studzinski, 2009; van Driel et al.,
2006; Woeckel et al., 2013). 1,25(OH)2D3 may also regulate
keratinocytes differentiation by increasing intracellular cal-
cium levels through the induction of the expression of
calcium receptor (CaR) and phospholipase C (PLC) which are
critical for calcium to stimulate keratinocyte differentiation
(Bikle, 2012). Additionally, Vit D has been shown to increase,
via AP-1 activation, the expression of several genes involved
in the regulation of keratinocytes differentiation such as
involucrin, transglutaminase, loricrin, and filaggrin and that
of cornified envelope formation while inhibiting the prolif-
eration of keratinocytes (Bikle, 2012). Moreover, time-
dependent changes in the expression of VDR co-activators
were noted during cell differentiation. It has been hypothe-
sized that these changes may contribute to the temporal
sequence of Vit D-mediated gene expression during keratino-
cytes differentiation (Bikle, 2012). 1,25(OH)2D3 has also
DOI: 10.3109/13880209.2014.988274 Vitamin D and cancer 9
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been shown to facilitate myogenic differentiation by increas-
ing the expression of IGF-II and Follistatin (Lee et al., 2010)
and by decreasing the expression of the insulin growth factor I
(IGF-I) and that of myostatin, a negative regulator of skeletal
muscle mass (Garcia et al., 2011; Lee et al., 2010). In
contrast, in human colon and breast cancer cells, Vit D
appears to foster tumor cell differentiation by increasing the
expression levels of proteins such as b-catenin and E-cadherin
(Lopes et al., 2012; Penda´s-Franco et al., 2008a). In
particular, on one hand, the binding of b-catenin to VDR
may cause the loss of this molecule from the transcriptional
complex TCF-4-b-catenin in the nucleus. This phenomenon
ultimately results in a decreased cell proliferation (Larriba
et al., 2013). One of the proposed mechanisms that may
account for the reduced cell proliferation associated with cell
differentiation induced by Vit D may be related, as
emphasized in Caco-2 cells, to the marked inhibitory effects
of this molecule on the expression of EGFR at both mRNA
and protein levels (Gocek & Studzinski, 2009). On the other
hand, in vitro studies on MDA-MB-453 human breast cancer
cells have shown that their treatment with 1,25(OH)2D3
resulted in accumulation of integrins, paxillin, and focal
adhesion kinase and their phosphorylation (Penda´s-Franco
et al., 2007). Conversely, the mesenchymal marker
N-cadherin and the myoepithelial marker P-cadherin resulted
down-regulated. These findings suggest that 1,25(OH)2D3
may revert the myoepithelial phenotype associated with
more aggressive forms of human breast cancer. However,
not all breast cancer cell lines show a similar response to
1,25(OH)2D3. The difference appears, in part, to be due to the
lack or decrease of VDR expression or function (Gocek &
Studzinski, 2009; Valrance et al., 2007). However, alterations
in 1,25(OH)2D3 metabolizing enzymes, which can decrease
Vit D levels below its effective concentration, cannot be ruled
out (Byrne & Welsh, 2007; Gocek & Studzinski, 2009). For
instance, in ER(+) breast cancer cell lines, 1,25(OH)2D3 may
facilitate cell differentiation by converging VDR and estrogen
receptor pathways to regulate BRCA-1, a tumor suppressor
gene that encodes a nuclear phosphoprotein that plays a role
in maintaining genomic stability (Campbell et al., 2000; Roy
et al., 2011). This effect contributes to regulating the balance
between differentiation and proliferation signaling (Campbell
et al., 2000; Gocek & Studzinski, 2009). Likewise breast
cancer, experimental observations provide evidence that
1,25(OH)2D3 may also induce differentiation in prostate
cancer cells (Gocek & Studzinski, 2009). To this end, in vitro
studies demonstrated that the treatment of LNCaP cells with
1,25(OH)2D3 up-regulates the expression of the androgen
receptor (AR) and increases the secretion of prostate-specific
antigen (PSA), a differentiation marker for epithelial prostate
cells (Gocek & Studzinski, 2009). The up-regulation of AR
may cause, in turn, an increase in the expression levels of
VDR which selectively enhances the AR-mediated androgenic
pro-differentiating effects but not the proliferation activity. In
contrast, microarray analysis by Krishnan et al. (2004)
demonstrates that in LNCAP tumor cells 1,25(OH)2D3
increases the expression of insulin-like growth factor-binding
protein-3 (IGFBP-3), which functions as an inhibitor of cell
proliferation, by up-regulating p21/Cip1 (Boyle et al., 2001).
In addition, Vit D treatment may also cause the up-regulation
of a ‘‘prostate differentiation factor,’’ a member of the bone
morphogenetic protein (BMP) family, which is generally
involved in growth and differentiation of embryonic and adult
tissues (Lambert et al., 2006). Interestingly, these studies
also revealed that 1,25(OH)2D3 regulates certain androgen-
responsive genes as well as genes that encode enzymes
involved in androgen catabolism. Prostate cancer cells are
also known to undergo ‘‘trans-differentiation’’ to a neuroen-
docrine phenotype which is an aggressive form of prostate
cancer. Recent evidence suggests a key role for NF-kB, as
well as IL-6, in this process (Mori et al., 2009). In this
context, Vit D up-regulates the expression of CCAAT/
enhancer-binding protein beta (C/EBP b), a transcriptional
activator that regulates genes involved in immune and
inflammatory responses, and which cooperates with NF-kB
in regulation of the secretion of IL-6 in neuroendocrine
human prostate cancer cells (Xiao et al., 2004). These data
suggest that 1,25(OH)2D3 may be promising as a potential
therapeutic agent in the treatment of this aggressive form of
prostate cancer. Experimental findings show that Vit D may
induce leukemic cells to differentiate. In particular, in vitro
studies show that the exposure of human myeloid leukemia
cells to physiological concentrations of 1,25(OH)2D3 for 36–
48 h induces their differentiation into functional monocytes
(Hughes et al., 2010). The differentiating activity of Vit D is
associated with the increased expression and/or activation of
different intracellular pathways such as protein kinase C
(PKC), PI3K/AKT pathway, p42 extracellular-regulated
kinase (p42-ERK), p38-ERK, and the c-Jun N-terminal
kinases (JNK) families of mitogen-activated protein kinases
(MAPKs) (Hughes et al., 2010). Pharmacological or genetic
blockade of these pathways may abrogate 1,25(OH)2D3-
driven monocytic differentiation.
Antioxidant defense and DNA
On one hand, free radicals, also known as reactive oxygen
species (ROS), in concert with reactive nitrogen species
(RNS) may play a dual role in cell homeostasis since they
may function as a second messenger in controlling cell
proliferation and differentiation. Furthermore, ROS may also
foster cellular senescence (Dro¨ge, 2003) and apoptosis (Circu
& Aw, 2010). The cumulative production of ROS and RNS
in response to endogenous or exogenous insults, i.e., the
‘‘oxidative stress’’, is a typical phenomenon that can be
observed in many types of cancer cells (Valko et al., 2006). A
redox imbalance occurring within these cells may ultimately
facilitate oncogenic stimulation. On the other hand, the
induction of antioxidant defense mechanisms may reduce the
biological impact of ROS (Valko et al., 2006). In line with
these observations, several in vitro and in vivo studies
highlight the fact that 1,25(OH)2D3 exerts antioxidative
activities on colorectal cancer (Nair-Shalliker et al., 2012).
In particular, it has been shown that DNA damage induced by
oxidative stress, as measured by the amount of 8-hydroxy-20-
deoxyguanosine, is high in the epithelium of the distal colon
of VDR-knockout mice and it is reduced in the epithelium of
human colon after a daily supplement of 800 IU (international
units) of Vit D (1 IU is the biological equivalent of 0.025mg
cholecalciferol or ergocalciferol) (Fedirko et al., 2010).
10 M. Giammanco et al. Pharm Biol, Early Online: 1–36
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These findings further suggest that Vit D may protect against
oxidative stress-induced DNA damage in humans. In line with
this hypothesis, Banakar et al. (2004) report that the treatment
of rats with calcitriol increases the expression of VDR and
markedly reduces the levels of malondialdehyde. However, no
substantial evidence has been obtained so far regarding a
direct relationship between Vit D and prevention of DNA
damage at a population level. Nevertheless, the clinical and
epidemiological observations that suggest a correlation
between deficient levels of calcidiol and increased incidence
of diseases associated with increased levels of DNA damage
in humans warrant further extensive investigation.
Induction of antioxidant enzymes
1,25(OH)2D3 is known to increase the expression of numerous
enzymes of the antioxidant defense system in humans (Fleet
et al., 2012). For instance, in vitro studies show that the
exposure of prostate cancer cells and MCF-7 breast cancer
cells to 1,25(OH)2D3 or its analogues induce the expression of
thioredoxin reductase 1 (TXNRD1), an enzyme that converts
thioredoxin to its reduced form needed to perform its
antioxidant function (Kovalenko et al., 2010; Peehl et al.,
2004; Swami et al., 2003). In addition, 1,25(OH)2D3 has been
shown to increase the production of superoxide dismutase 1
(SOD1) and 2 (SOD2) in prostate epithelial cells (PECs) and
in androgen-sensitive prostate cancer cells (LNCaP), respect-
ively (Lambert et al., 2006; Peehl et al., 2004). Furthermore,
other in vitro observations show that the treatment of the
human prostate epithelial cell line RWPE-1, and that of BPH-1
benign prostatic hyperplasia (BPH) epithelial cell line or
OVCAR3 ovarian carcinoma cell line, with 1,25(OH)2D3,
increases the intracellular levels of glucose-6-phosphate
dehydrogenase (G6PDH), an enzyme which regulates the
intracellular levels glutathione (Bao et al., 2008; Kovalenko
et al., 2010; Zhang et al., 2005). This effect ultimately protects
cells from apoptosis induced by H2O2. These findings are in
line with experimental evidence showing that the expression
levels of G6PDH in prostatic epithelial cells are modulated by
1,25(OH)2D3 through VDRE located in the first intron of the
gene coding for G6PDH (Bao et al., 2008). However, this
phenomenon was not observed in DU145 and CWR22 prostate
cancer cells (Bao et al., 2008). The different responses of these
cell lines to 1,25(OH)2D3 treatment may be, in part explained,
with the loss of AR expression, which is a characteristic of
tumor cells less susceptible to Vit D treatment (Stewart &
Weigel, 2004; Ting et al., 2007a,b). Furthermore, the protec-
tion from oxidative stress mediated by Vit D, may also be
indirectly due to the induction of the nuclear factor erythroid-
derived 2-Like 2 (NFE2L2), a transcription factor that controls
the gene expression of several enzymes of the antioxidant
systems such as glutathione peroxidase 3 (GPX-3), heme
oxygenase 1 (HMOX-1), and aldo-keto reductase 1C2
(AKR1C2) (Kovalenko et al., 2010). The effects of Vit D on
the oxidative system further support the clinical benefit of this
molecule in cancer chemoprevention.
Regulation of proteins involved in DNA repair
Experimental in vivo observations show that VDR-deficient
mice are more susceptible to the development of skin tumors
either induced by chemical carcinogens such as 7,12-
dimethylbenzanthracene (DMBA) or by chronic UVR expos-
ure (Bikle, 2012). These studies suggest that 1,25(OH)2D3
may protect the skin from malignant transformation by
controlling keratinocyte proliferation and differentiation,
by facilitating DNA repair, and by suppressing the activation
of the hedgehog (Hh) pathway following UVB exposure
(Bikle, 2012). In particular, recent studies show that
1,25(OH)2D3 may protect DNA by regulating the expression
of genes coding for DNA repair enzymes (Krishnan et al.,
2004; Nair-Shalliker et al., 2012). In this context, Akhter et al.
(1997) have reported that in SCC cells, Vit D analog EB1089
induces the overexpression of the growth arrest and DNA-
damage-inducible a (GADD45a) gene, a p53 target gene
whose products are involved in DNA repair. It has also been
shown that the treatment of ovarian cancer cells with
1,25(OH)2D3, causes cell-cycle arrest at the G2/M transition
through p53-independent induction of GADD45 (Jiang et al.,
2003a,b). The role of GADD45 induction in eliciting the
chemopreventive effects of Vit D is supported by the findings
that cell-cycle arrest in G2 or in M induced by 1,25(OH)2D3
does not occur following GADD45 deletion (Akter et al.,
1997; Jiang et al., 2003a). Furthermore, microarray analyses
performed in MCF-7 breast cancer cells show that the
treatment of these cells with 1,25(OH)2D3 increases the
mRNA expression levels of other molecules involved in DNA
repair such as p53 and proliferating cell nuclear antigen
(PCNA) (Swami et al., 2003). Additionally, more recent
studies show that 1,25(OH)2D3 treatment can protect BPH-1
human prostate epithelial cells from carcinogen-induced
genotoxic stress via VDR-mediated transcriptional upregula-
tion of DNA repair genes, ATM and RAD50, thereby
facilitating DNA double-strand break repair (Ting et al.,
2012). Interestingly, on one hand, recent findings stress that in
BRCA1-deficient breast cancer cells, Vit D prevents the
degradation of the DNA repair protein 53BP1 mediated by
cysteine proteinases Cathepsin L (Gonzalo, 2014), a lyso-
somal endopeptidase which is involved in tumor cell prolif-
eration, invasion, and metastasis (Gonzalo, 2014; Lankelma
et al., 2010; Leto et al., 2010). On the other hand, recent
observations report that the gene encoding the BRCA1 protein
is a critical downstream target of Vit D. Consistent with these
data Campbell et al. (2000) show that treatment of MCF-7
cells with calcitriol results in a near 6-fold increase in BRCA1
protein and that VDR expression is directly correlated with
induction of BRCA1.
Effects of Vit D on the synthesis and metabolism of
prostaglandins
It is well established that prostaglandings (PGs) may promote
cancer cell proliferation and progression (Wang & Dubois,
2010). Since experimental findings demonstrate that
1,25(OH)2D3 may act as a negative modulator of the synthesis
and activity of prostaglandins (PGs) (Krishnan & Feldman,
2010; Moreno et al., 2006), these effects may also, in part,
account for the chemo-preventive activity of Vit D on tumor
progression. In support of this hypothesis, recent studies have
better defined the role of prostaglandin–endoperoxide syn-
thase, a key enzyme of prostaglandin synthesis and more
DOI: 10.3109/13880209.2014.988274 Vitamin D and cancer 11
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widely known as cyclooxygenase (COX), on carcinogenesis
(Wang & Dubois, 2010). Increasing experimental and clinical
observations show that the inducible isoform of this enzyme,
namely COX-2, is overexpressed in many human tumors and in
cancer cell lines. Moreover, these findings also show positive
relationship between COX-2 overexpression and tumor pro-
gression (Cordes et al., 2012; Krishnan & Feldman, 2011; Thill
et al., 2012). Alterations in the expression of COX-2 and its
product, prostaglandin E2 (PGE2), have been observed in
breast cancer and colorectal cancer where these molecules
appear to be involved in several key steps of malignant
progression such as tumor initiation, tumor cell proliferation,
and metastasis formation (Thill et al., 2012; Wang & Dubois,
2010). Thus, COX-2 may be considered an appropriate target
for cancer chemoprevention and treatment. To this end, some
in vitro studies carried out on LNCaP and PC-3 prostate cancer
cells have shown that the treatment with 1,25(OH)2D3
decreases the expression levels of COX-2 and that of prosta-
glandin receptors EP2 and FP, whereas it increases the
expression of 15-hydroxyprostaglandin-D dehydrogenase (15-
PGDH) a NAD+-dependent enzyme involved in the degrad-
ation of PGE2 (Krishnan & Feldman, 2010; Moreno et al.,
2005). Interestingly, Thill et al. (2012) have recently reported
that VDR and COX-2 expressions are inversely correlated in
malignant breast cell lines. This phenomenon has also been
observed in ovarian cancer tissues (Cordes et al., 2012). These
findings support the hypothesis that 1,25(OH)2D3 may inhibit
tumor cell proliferation by reducing the intracellular levels of
biologically active prostaglandins. In line with these observa-
tions, more recent in vitro studies by Yuan et al. (2012) report
that a 72-h exposure of MCF-7 breast cancer cell to
1,25(OH)2D3 results in a significant decrease of COX-2
mRNA expression levels and in that of PGE2 in cell culture
supernatant. These data suggest a possible therapeutic effect-
iveness of the association calcitriol with non-steroidal anti-
inflammatory drugs (NSAIDs) in the prevention and treatment
of breast and prostate cancers (Krishnan & Feldman, 2010;
Moreno et al., 2005). This drug association may also have the
vantage of lowering the dose of NSAIDs thus reducing their
toxic effects (Moreno et al., 2005).
Target cells of Vit D
Effects of Vit D on cancer stem cells
Vit D is one of the molecules involved in the regulation of
stem cell homeostasis. 1,25(OH)2D3 exerts its important
biological effects on both adult stem cells (ASC) (Cianferotti
et al., 2007; Zhou et al., 2010) and cancer stem cells (CSCs)
(Feldman et al., 2014; Maund et al., 2011; So et al., 2011).
DNA repair and protection from oxidative damage are
processes that mainly affect ASCs, while cell-cycle arrest
and induction of apoptosis limit the expansion of the CSCs
population. Extensive research has recently been carried out
to evaluate the direct effects of 1,25(OH)2D3 on stem cells
(Fleet et al., 2012). Most of the experimental data regarding
the molecular mechanisms underlying the inhibiting effects of
1,25(OH)2D3 on CSC growth and differentiation have been
obtained following investigations carried out on primary
cancer cell cultures or on established cancer cell lines (Pervin
et al., 2013). These studies highlighted the fact that in mice
the proliferation of prostate stem cells was inhibited by
1,25(OH)2D3. Further experiments performed to better clarify
the possible mechanisms underlying this effect showed that
the interaction between Vit D and VDR stimulates the
production of interleukin-1a (IL-1a) (Maund et al., 2011).
This pro-inflammatory cytokine, in turn, mediated the anti-
proliferative effects of 1,25(OH)2D3 in adult prostate pro-
genitor/stem cells (PrP/SC) by promoting cell-cycle arrest and
senescence (Maund et al., 2011). Furthermore, Fedirko et al.
(2009) have recently shown that 1,25(OH)2D3 treatment and
calcium supplements decrease the expression of the human
telomerase reverse transcriptase (hTERT) in cells of the upper
portion of the colon. These observations indicate that Vit D
may indirectly inhibit the expansion of this cell population
and protect it from potential genetic mutations. In line with
these observation, Kasiappan et al. (2012) described how
1,25(OH)2D3 decreases the mRNA expression of hTERT by
inducing the expression of non-coding small RNA
microRNA-498 (miR-498) in ovarian tumor cells. These
effects ultimately result in the suppression of ovarian cancer
growth. Finally, 1,25(OH)2D3, and its analogues have been
reported to regulate the expression of CD44, a specific marker
of breast cancer stem cells, in human breast cancer cells
in vitro (Parvin et al., 2013; So et al., 2011). These studies
provide a basis for preclinical and clinical evaluations of Vit
D and its analogues for chemoprevention of cancer stem cells.
These observations warrant more extensive studies to assess
the impact of Vit D on cancer stem cells.
Effects of vitamin D on vascular cells and angiogenesis
Growing evidence indicates that Vit D may play an important
role in the inhibition of tumor angiogenesis (Vanoirbeek et al.,
2011; Xu et al., 2013). This peculiar function has been
defined with the term ‘‘angioprevention’’ (Tosetti et al.,
2002). On one hand, experimental studies suggest that the
preventive activity of 1,25(OH)2D3 on tumor angiogenesis
might be the consequence of the effects of this molecule on
vascular endothelial cells (EC) (Furigay & Swamy, 2004;
Mantell et al., 2000). On the other hand, in vitro observations
have highlighted the presence of VDR on cultured bovine
aortic endothelial cells, in human capillary and in venous
endothelial cells (Chung et al., 2006, 2009; Merke et al.,
1989). In addition, the expression of the enzyme 1a-
hydroxylase, a key enzyme involved in the biosynthesis of
1,25(OH)2D3, has also been reported in these cells (Chung
et al., 2009; Merke et al., 1989; Suzuki et al., 2009; Zehnder
et al., 2002). Early experimental investigations by Mantell
et al. (2000), aimed at evaluating the effect of Vit D on
angiogenesis, show that 1,25(OH)2D3 may inhibit the expres-
sion of the vascular endothelial growth factor (VEGF) and the
formation of new blood vessels in mice transplanted with
MCF7 human breast cancer, a tumor which expresses high
levels of VEGF. In prostate cancer, 1,25(OH)2D3 has been
reported to decrease the expression of VEGF through
transcriptional repression of the hypoxia-inducible factor
1(HIF-1) (Ben-Shoshan et al., 2007). Furthermore, in SCC
tumor cells, 1,25(OH)2D3 has been observed to suppress
the expression of the proangiogenic factor IL-8 via NF-
kB-dependent pathway thus leading to the inhibition of
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endothelial cell migration and tube formation (Bao et al.,
2006). The specific mechanisms underlying this phenomenon
consist in a reduced translocation of the p65 subunit of NF-kB
to the nucleus that results in a decreased transcription of IL-8
gene mediated by NF-kB. Furthermore, Chung et al. (2009)
have highlighted the fact that, in VDR wild-type (WT) or
VDR knockout mice inoculated with transgenic adenocarcin-
oma of the mouse prostate (TRAMP), the tumor vessels are
enlarged and their volume increased in KO mice thus
suggesting a negative regulation of VDR-Vit D on tumor
angiogenesis. These investigations additionally showed that
VDR knockout mice had increased expression levels of pro-
angiogenic factors such as HIF-1, VEGF, angiopoietin-1
(Ang-1), and platelet-derived growth factor (PDGF). Vit D
can increase VEGF mRNA levels in vascular smooth muscle
cells (Cardu´s et al., 2006) while in SW480-ADH human colon
tumor cells, this molecule has been shown to upregulate the
mRNA levels of thrombospondin-1 (THSD1), a potent anti-
angiogenic factor (Fernandez-Garcia et al., 2005). Other
studies aimed at investigating the effect of 1,25(OH)2D3 on
normal endothelial cells and tumor-derived endothelial cells
(TDECs) showed effects of 1,25(OH)2D3 greater than those
elicited in the normal aortic endothelial cells or yolk sac
endothelial cells (MYSECs) (Chung et al., 2009).
Furthermore, Vit D analogues, EB1089, Ro 25-6760, and
ILX23-7553, also showed a potent antiproliferative activity
against TDECs (Bernardi et al., 2002). It has been also
demonstrated that the Vit D-dexamethasone association was
more effective in inhibiting TDECs growth than each single
agent (Chung et al., 2009). Other in vitro observations
reported that, in TDECs, Vit D increased the intracellular
levels of VDR and that of the pro-apoptotic protein p27 which
reduces the concentration of signal molecules for angiogen-
esis, including angiopoietin-2 (Bernardi et al., 2002; Flynn
et al., 2006). Interestingly, on one hand, Chung et al. (2006)
compared the effects of calcitriol on SCC TDECs and
endothelial cells derived from matrigel (MDECs). These
authors pointed out that both these cell types expressed VDR
and the interaction with 1,25(OH)2D3 resulted in a 47%
growth inhibition of TDECs and in a 12.3% growth inhibition
of MDECs. Furthermore, in TDECs, Vit D caused cell-cycle
arrest in the G0/G1 phase and a decrease of the number of
cells in the S phase, due to the induction of p27 and the down-
regulation of p21. These data indicated that TDECs are more
susceptible than MDECs to the anti-proliferative effects of
1,25(OH)2D3. On the other hand, Flynn et al. (2006) showed
that 1,25(OH)2D3 regulated the expression of several proteins
involved in TDEC differentiation and apoptosis. These
authors reported that although VDR is present in TDECs
and MYSEC and Vit D upregulated VDR in these cells, a 48-
h exposure of the cells to dexamethasone further increased
VDR expression. Finally, no increase in the intracellular
levels of CYP24A4, the predominant enzyme involved in the
catabolic inactivation of 1,25(OH)2D3 in normal tissues, was
found in TDECs. Conversely this phenomenon occurred in
MYSECs (Flynn et al., 2006). In line with these findings,
Chung et al. (2006) have demonstrated that TDECs may be
more sensitive to calcitriol due to novel epigenetic silencing
of CYP24A1. Therefore, the direct effects of calcitriol on
endothelial cells may play a role in the calcitriol-mediated
antitumor activity observed in vivo in animal tumor models.
Furthermore, in vitro studies on RWPE1 prostatic epithelial
cells highlighted treatment with 1,25(OH)2D3 as causing
growth arrest (Kovalenko et al., 2010). The subsequent
genomic analysis revealed a decrease in the expression level
of genes coding for NF-kB and IGF-1. Additionally, the
inhibition of the transcription of pro-inflammatory cytokines,
including IL-1, IL-6, and IL-17, was noted as occuring after
about a 6-h exposure. The same studies also showed that
1,25(OH)2D3 caused a reduction of VEGF and VEGF
receptors mRNA levels, including the kinase insert domain
receptor (KDR) and neuropilin 1 (NRP1) and the induction of
anti-angiogenic factors and that of molecules involved in the
protection of cells from oxidative stress and in the homeo-
stasis of cellular redox (Kovalenko et al., 2010). Finally, it
was shown that, in RWPE1 cells, 1,25(OH)2D3 induced the
expression of numerous isoforms of semaphorins, including
SEMA 3B, 3F, and 6D (Kovalenko et al., 2010). As these
molecules may antagonize the proangiogenetic effects of
VEGF by a competitive binding to receptor NRP1, this may
also partly account for the growth-inhibiting effects of Vit D
on prostate cancer cells. An additional mechanism of the
preventive effects of Vit D on tumor angiogenesis involves its
ability to inhibit COX-2 expression levels (Aparna et al.,
2008). COX-2 has been shown to exert indirectly its
promoting effects on tumor angiogenesis by increasing the
synthesis of HIF-1a protein in cancer cells (Sahin et al.,
2009). Therefore, the inhibition of this enzyme may result in a
decreased growth activity of tumors. Moreover, 1,25(OH)2D3
strongly represses DICKKOPF-4 (DKK4), a weak WNT
antagonist that promotes invasion and angiogenesis in
cultured colorectal cancer (CRC) cells and that is up-
regulated in human colon tumors (Penda´s-Franco et al.,
2008b). All these effects may also, in part, account for the
significant inhibition of metastasis observed in murine models
of prostate and lung cancer treated with Vit D.
Regulation of immune function by vitamin D
Vit D and the immune system
The role of Vit D, as an immunomodulator, was well
established nearly 30 years ago (Rook et al., 1986). The
effects of Vit D on immune system appear to be closely linked
to the chemopreventive effects on tumors (Fleet et al., 2012).
The possible role of Vit D in the regulation of immune
responses is strongly supported by the findings that almost all
immune cells, including T cells, B cells, monocytes, neutro-
phils, platelets, macrophages, and dendritic cells express Vit
D receptors and that Vit D appears to modulate the activity of
these cells (Hewison, 2011). The ligand for VDR also showed
a synergic activity with Vitamin A, Vitamin K2, and certain
chemotherapeutic agents (Funato et al., 2002; James et al.,
1999). Interestingly, only naive T cells display very low VDR
levels, while this receptor is abundantly present upon T cell
activation (Hewison, 2011). However, the differentiation of
monocyte into macrophages or dentritic cells (DCs) has been
shown to be associated with a decrease in VDR-expression,
making these cells less sensitive to 1,25(OH)2D3 (Hewison,
2011). In this context, 1,25(OH)2D3 has been recognized as an
important mediator of innate immune responses, enhancing
DOI: 10.3109/13880209.2014.988274 Vitamin D and cancer 13
D
ow
nl
oa
de
d 
by
 [G
ae
tan
o L
eto
] a
t 0
3:0
4 2
4 M
ay
 20
15
 
the antimicrobial properties of immune cells such as mono-
cytes and macrophages (Hewison, 2011). There is evidence
that Vit D modulates the expression of many genes in cells of
the innate immune system which encode for proteins that are
crucial for autophagy and for the antimicrobial activity
(Hewison, 2011). In particular, one of these studies reported
that Vit D increased the expression levels of genes encoding
for the antimicrobial peptides human cathelicidin (CAMP)
and b defensin-1 (DEFB1) in isolated human keratinocytes,
monocytes, and neutrophils (Wang et al., 2004). These
molecules form the first line of host defence against microbial
pathogens. Another study showed that 1,25(OH)2D3 markedly
induced the expression of CAMP and, to a lessen extent, that
of defensin b2 (DEFB2/HBD2) in different cell types such as
colon cancer, acute myeloid leukemia, keratinocytes, human
bone marrow cells-derived macrophages, and bone marrow
cells (Gombart et al., 2005). These effects occurred following
the interaction of Vit D with a specific VDRE present in the
promoter region. In particular, in vitro studied showed that
1,25(OH)2D3 stimulates the expression of the pattern recog-
nition receptor NOD2/CARD15/IBD1 gene in primary human
monocytic and epithelial cells. As a consequence of the
NOD2 downstream signaling activation, a stimulation of NF-
kB transcription factor function occurs. This effect, in turn,
induces the expression of the gene-encoding antimicrobial
peptide defensin b2 (DEFB2/HBD2) (Wang et al., 2010a).
Furthermore, numerous cytokines can modulate the metabol-
ism of Vit D in macrophages, monocytes and dendritic cells
(Hewison, 2011). The pro-inflammatory cytokines such as
IFN-g and TNF-a stimulate the synthesis of 1,25(OH)2D3 by
increasing the expression of CYP27B1 in monocytes
(Zehnder et al., 2002). On the other hand, several inflamma-
tory cytokines and agonists of toll-like receptor (TLR), which
are transmembrane proteins involved in recognizing and
defending against invading pathogens, may increase the
expression of CYP27B1 and that of VDR in dendritic cells
(Sze´les et al., 2009). In contrast, IL-4 produced by type-2
T-helper lymphocytes potentiates CYP24 gene expression in
monocytes, leading to the formation of inactive metabolite
24,25-dihydroxyvitamin D3 (Edfeldt et al., 2010). These
effects may alter the intracellular levels Vit D metabolites
which, in turn, can modulate the function of other immune
cells in the microenvironment. Numerous studies have
demonstrated that 1,25(OH)2D3 is also involved in the
regulation of cell functions of the adaptive immune system
(Hewison, 2011). Consistent with these findings, Vit D
deficiency has been associated with the development of several
autoimmune diseases, including ulcerative colitis, Crohn’s
disease, and also infectious diseases (Cantorna, 2012; Meeker
et al., 2014). However, a very limited number of studies have
been performed to assess the role of the immune regulatory
function of Vit D in cancer. In this context, Krishnan et al.
(2007) reported that calcitriol exhibits anti-inflammatory
effects that may account for its inhibitory activity in prostate
cancer. More recently, Bessler and Djaldetti (2012) showed
that Vit D alters the relationship between immune and cancer
cells leading to a significant decrease in the pro-inflammatory
cytokines TNF-a and IL-6. On the basis of these results, these
authors hypothesized that the reduced production of pro-
inflammatory cytokines induced by Vit D may lead to a
suppression of tumor development. Furthermore, recent
studies by Young and Day (2013) showed that the time
elapsing before cancer recurrence following surgical treatment
was increased by over 3-fold in head and neck patients
receiving 1,25(OH)2D3 as compared with untreated patients.
This phenomenon was associated with, and increased, differ-
entiation of blood-derived CD34+ cells into dendritic cells and
to a decrease in the peripheral blood and intratumoral levels of
immunosuppressive CD34+ cells.
Chemopreventive effects of Vit D on specific tumors:
possible mechanisms of action
Effects of vitamin D on breast cancer cells
In vitro and in vivo studies carried out in order to assess the
effects of 1,25(OH)2D3 and its semisynthetic analogues on
breast cancer cell proliferation and malignant progression
showed that different ligands of the VDR are equally effective
in inhibiting the growth of ER(+) breast cancer cell lines such
as MCF-7, T-47-D, ZR-75-1, SKBR-3 (Krishnan et al., 2012),
and ER() breast cancer cell lines such as BT-20, MDA-MB-
435, MDA-MB-231, and SUM-159PT (Flanagan et al., 2003;
Mehta et al., 2012). These data are in agreement with the
clinical observations that describe the therapeutic benefit of
Vit D and its analogues in both ER(+) and ER() breast cancer
(Krishnan et al., 2012; Lee et al., 2008; Li & Brown, 2009;
Mehta et al., 2012). Although the exact mechanisms by which
Vit D may exert its growth inhibitory activity on breast cancer
cells has not yet been fully understood, in vitro observations
indicate that this molecule may affect tumor cell proliferation
by causing cell-cycle arrest in the G0/G1 phase, by promoting
apoptosis and by inhibiting tumor angiogenesis (Li et al.,
2005; Nagpal et al., 2005; Vanoirbeek et al., 2011). The
inhibiting effects of Vit D on cell-cycle arrest in G0/G1 entry
appears to be due to an increase of the expression of cyclin
kinase inhibitors CDKIs, including p21 and p27 which inhibit
cell-cycle progression by blocking the activity of CDK
complexes with VDR ligands (Jensen et al., 2001; Krishnan
et al., 2012). Furthermore, studies carried out on the MCF-7
cell line showed that 1,25(OH)2D3 reduced, in a time-
dependent fashion, the intracellular levels of CDK2, CDK4,
cyclin D1, and cyclin A (Jensen, 2001; Lowe et al., 2003;
Verlinden et al., 1998). In particular, 1,25(OH)2D3 was shown
to prevent the activation of the cyclin D1-CDK4 complex, to
decrease cyclin D3 expression, and to inhibit the E2F
transcription factor thus decreasing the expression of cyclin
A (Jensen et al., 2001). However, on one hand, the
antiproliferative effects of Vit D on breast cancer cells also
appears to be mediated by the induction of TGF-b (Colston &
Hansen, 2002; Koli & Keski-Oja, 1995; Proietti et al., 2011)
and by the suppression of the protoncogene c-myc expression
(Jensen et al., 2001; Lopes et al., 2012; Saunders et al., 1993).
In addition, Vit D can block the proliferative activity of
insulin and IGF-1, most likely by increasing the expression of
IGFBP-3 and IGFBP-5 (Colston et al., 1998; Lee et al., 2006;
Rozen et al., 1997). On the other hand, the promoting effect of
Vit D on apoptosis in breast cancer cells appears to be the
result of decreased levels of Bcl-2, a redistribution of Bax, a
release of cytochrome c, and DNA fragmentation (Nagpal
et al., 2005; van den Bemd & Chang, 2002). Furthermore, it
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was demonstrated that 1a,25(OH)2D3 is involved in the
inhibition of transcriptional activity of NF-kB in breast cancer
cells (Tse et al., 2010). In addition to their direct growth-
inhibiting effects, VDR ligands may also inhibit angiogenesis
and decrease the invasive and metastatic potential of breast
cancer cells in vitro and in vivo (Hansen et al., 1994; Mantell
et al., 2000; van den Bemd & Chang, 2002; Vanoirbeek et al.,
2011). These results support the concept that the combination
of VDR ligands with the most common clinically available
antitumor agents used in breast cancer treatment might result
in a more effective therapeutic response (Krishnan &
Feldmann, 2011). This hypothesis has been further sustained
by in vitro studies which demonstrated that 1,25(OH)2D3
enhances the cytotoxic effects of doxorubicin, paclitaxel,
adriamycin, cisplatin, and those induced by irradiation on
tumor cells (Chaudhry et al., 2001; Lawrence et al., 2013;
Sundaram et al., 2000). Interestingly, recent observations
show that Vit D prevents genomic instability due to the
Cathepsin L-mediated degradation of DNA repair protein
53BP1 in BRCA-1-negative breast cancer cells (Gonzalo,
2014). These results suggest that Vit D may be of clinical
relevance in the treatment of aggressive form of breast cancer
such as triple-negative BRCA-1-deficient ones.
Vit D on breast cancer: clinical studies
The epidemiologic studies regarding the association between
Vit D and breast cancer risk have generated conflicting results
so far (Engel et al., 2010; Freedman et al., 2007; Khan et al.,
2010; Maalmi et al., 2014; Mehta et al., 2012; Mohr et al.,
2011; Rose et al., 2013). For instance recent clinical obser-
vations showed a significant inverse association between
1,25(OH)2D3 serum concentration and risk of breast cancer
with a more pronounced decrease in risk in premenopausal
than in perimenopausal women (Engel et al., 2010; Maalmi
et al., 2014; Mohr et al., 2011; Mehta et al., 2012). In line with
these findings, other clinical investigations reported that
women with 1,25(OH)2D3 serum concentrations greater than
52 ng/ml showed a significant decrease (50%) in the risk of
breast cancer compared with women with circulating levels of
1,25(OH)2D3 lower than 13 ng/ml (Bertone-Johnson et al.,
2005; Garland et al., 2007; Lowe et al., 2005). Furthermore,
women with 1,25(OH)2D3 serum concentrations above 27 ng/
ml showed a decreased risk of breast cancer by 27%, compared
with those with circulating levels of this molecule lower than
19.8 ng/ml (Engel et al., 2010). These data also showed that
the preventive effects of a high plasma concentration of
1,25(OH)2D3 on the onset of breast cancer were more
pronounced in women with normal body mass index (BMI),
i.e., lower than 25 kg/m2 (Engel et al., 2010). These findings
also indicate that, in order to maintain plasma concentrations
of 1,25(OH)2D3 higher than 30 ng/ml, women leading a
sedentary life style and who are exposed for a short period of
time to sunlight require an intake of at least 2000 IU/d
(Garland et al., 2007). Alternatively, it was calculated that
12 min per day of continuous exposure to sunlight and the
exposure of at least the 50% skin surface is approximately
equivalent to an oral administration of 3000 IU of Vit D (Engel
et al., 2010; Holick, 2013). However, the optimal cut-off levels
of Vit D and the threshold values below which a subject may
be considered Vit D deficient are still controversial. The
optimal dose currently suggested to be administered in order to
prevent deleterious consequences due to hypercalcemia is
30 ng/ml (Khan et al., 2010). Foods naturally rich in Vit D
content more widely consumed by the population are fish
(55%), meat (23.5%), cheese (6.8%), and eggs (5.6%).
However, no consistent association of breast cancer risk with
the consumption of meat, eggs, or dairy foods have been
highlighted so far, while the correlation between fish intake
and breast cancer incidence still remains debatable (Engeset
et al., 2006; Kim et al., 2009; Pala et al., 2009). The
geographical area of residence, such as in the case of northern
and southern Italy, has been shown to be an important factor in
influencing the endogenous synthesis of Vit D (Rossi et al.,
2009). In fact, an inverse association between Vit D and breast
cancer was observed to be much higher in women in southern
Italy compared with women in the northern part of the country
because of longer exposure to sunlight (Rossi et al., 2009).
However, conflicting results on the relationship between skin
pigmentation and Vit D synthesis were obtained following a
study carried out in United States to assess the risk of breast
cancer when comparing women of Latin American origin
(Hispanic women) and non-Hispanic white women (John
et al., 2007; Rollison et al., 2012). Overall these studies
showed an inverse relationship between Vit D intake and
incidence of breast cancer either in premenopausal women or
in post-menopausal women (Anderson et al., 2010; Rollison
et al., 2012; Shin et al., 2002). In addition, circulating levels of
Vit D were shown to be associated with increased breast
cancer mortality (Goodwin et al., 2009; Mohr et al., 2011; Yao
& Ambrosone, 2013). On one hand, ethnic difference and the
degree of skin pigmentation have provided important evidence
that exposure to sunlight is the main source of Vit D and that
this phenomenon stimulates the synthesis and increases the
concentrations of circulating 1,25(OH)2D3 (Armas et al.,
2007; John et al., 2007; Knight et al., 2007; Rollison et al.,
2012; Yao & Ambrosone, 2013). On the other hand, discrepant
results regarding the relationship between existing pigmenta-
tion of the skin and ability to synthesize Vit D have been
obtained from other studies (Bogh et al., 2010; John et al.,
2007; Rollison et al., 2012). Increased skin pigmentation
reduced the dose of UV exposure, consequently it may cause a
decreased synthesis of Vit D. The Hispanic women showed
lower levels of circulating Vit D than white women exposed to
the same amount of sunlight and, consequently, an increased
incidence of breast cancer and mortality (Mohr et al., 2011;
Yao & Ambrosone, 2013). The integration of Vit D in one’s
diet, in particular among Hispanic women, had a considerable
impact on Vit D circulating levels and on the incidence of
breast cancer (John et al., 2007; Mohr et al., 2011; Rollison
et al., 2012; Yao & Ambrosone, 2013). Overall these studies
do not fully clarify whether Vit D is associated with a reduced
risk of breast cancer. Further investigation may better define
the clinical impact of vitamin supplementation in breast cancer
development and treatment.
Effects of vitamin D on prostate cancer cells
Experimental and clinical studies provide evidence of a
positive correlation between Vit D deficiency and prostate
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cancer (Swami et al., 2011). The findings showing that VDRs
are expressed in normal prostate tissue, in benign prostate
hyperplasia (BPH), and in prostate cancer cells suggest that
BPH and prostate cancer (PCa) may represent potential
targets for VDR ligands (Adorini et al., 2007; Crescioli et al.,
2002; Hendrickson et al., 2011; Krill et al., 2001; Munetsuna
et al., 2011; Swami et al., 2011). Several experimental
observations have highlighted the fact that VDR ligands may
exert numerous effects on prostate cancer cells including cell-
cycle arrest in the G0/G1 phase, apoptosis, and interaction
with androgen-mediated signaling (Guzey et al., 2002; Nagpal
et al., 2005; Zhuang & Burnstein, 1998). VDR has also been
shown to repress COX-2 and enhance expression of hydro-
xyprostaglandin dehydrogenase 15-(NAD) (HPGD), the
combined effects of which can serve to limit prostate cancer
cell growth through an overall reduction in prostaglandin
activity (Moreno et al., 2005). Consistent with this hypoth-
esis, earlier studies by Zhao et al. (1997) showed that the
androgen antagonist Casodex suppresses the antiproliferative
effect of 1,25(OH)2D3 in LNCaP cells, indicating that the AR
is involved in 1,25(OH)2D3-mediating signaling.
Experimental evidence shows that the growth inhibition
mediated by VDR ligands appears to be the result of a
decrease in CDK2 activity and an increase in the expression
of p21, p27, IGFBP-3, IGFBP-5, and E-cadherin (Drivdahl
et al., 1995; Guzey et al., 2002; Huynh et al., 1998; Krishnan
et al., 2004; Zhuang & Burnstein, 1998). In addition, in some
prostate cancer cells, Vit D has been shown to down-regulate
some anti-apoptotic genes such as Bcl-2 (Chen & Holick,
2003; Guzey et al., 2002). Recent cDNA analysis of normal
prostate cells and LNCaP prostate cancer cells treated with
1,25(OH)2D3 contributed to identifying the target genes and
to clarifying, in part, the mechanism of Vit D-induced tumor
cell growth inhibition (Krishnan et al., 2004; Peehl et al.,
2004). These studied have reported the overexpression of the
gene-encoding 24-hydroxylase, the enzyme which catalyzes
the first step of the catabolic degradation of 1,25(OH)2D3
(Chen et al., 2012; Krishnan et al., 2004; Muindi et al., 2007,
2010). These observations imply that the use of 24-
hydroxylase inhibitors may increase the inhibitory activity
of 1,25(OH)2D3 and that of its synthetic analogues (Muindi
et al., 2010). Other possible mechanisms underlying the
growth-inhibiting activity of Vit D on prostate cancer cells
include stimulation of differentiation, modulation of growth
factor activity, and inhibition of tumor angiogenesis, invasion,
and metastasis (Krishnan & Feldman, 2011; Marchiani et al.,
2006; Stio et al., 2011). Moreover, it has been also reported
that, in normal and malignant prostate cells, 1,25(OH)2D3
may induce the expression of enzymes implicated in the
maintenance of redox balance and protection of cells from
oxidative damage such as TXNRD1 and SOD-2 (Peehl et al.,
2004). Although a direct inhibiting effect of these enzymes in
prostate cell growth inhibition appears unlikely, it is reason-
able to hypothesize that they may indirectly mediate the
chemopreventive effects of 1,25(OH)2D3 by preventing DNA
damage caused by ROS. Finally, recent finding by Hsu et al.
(2011) show that Vit D may indirectly affect tumor cell
invasion and metastasis by facilitating prostate cancer cell
aggregation through the increase of E-cadherin expression.
However, Ajibade et al. (2014) recently reported that
prolonged treatments with calcitriol in homozygous male
TRAMP mice resulted in the development of a resistant and
more aggressive form of prostate cancer associated with
increased distant organ metastasis. Although the possible
mechanism(s) facilitating these effects were not defined, these
results support the concept that Vit D compounds may be
effective in slowing or preventing progression of prostate
cancer of earlier stages.
Clinical studies with prostate cancer
The data obtained following epidemiological studies on the
effects of 1,25(OH)2D3 on prostate cancer are not univocal
(Gilbert et al., 2012; Hendrickson et al., 2011; Krishnan &
Feldman, 2011; Kristal et al., 2014; Swami et al., 2011). In
fact, whereas some studies demonstrated a strong inverse
association between Vit D serum concentrations and risk of
prostate cancer (Gilbert et al., 2012; Tretli et al., 2009), other
investigations show no significant correlation between Vit D
circulating levels and serum PSA (Gilbert et al., 2012). More
recently Kristal et al. (2014) reported that low and high Vit D
concentrations were associated with increased risk of prostate
cancer. This association resulted stronger for high-grade
disease. Other clinical studies have highlighted the effective
therapeutic potential of Vit D when administered alone or in
combination with other cytostatic agents (Beer, 2008;
Hershberger et al., 2001; Krishnan & Feldman, 2011; Ma
et al., 2010; Nagpal et al., 2005; Swami et al., 2011;
Wigington et al., 2004). In addition, these studies have
provided the rationale for a combination calcitriol–taxanes
therapy in patients with prostate cancer (Beer et al., 2008;
Ting et al., 2007a,b). On the basis of these considerations,
many clinical studies have been undertaken in androgen-
independent prostate cancer patients where Vit D3 was often
combined with standard cancer therapies. However, although
these drug associations were well tolerated and the addition of
Vit D3 did not result in any additional toxicity, when
compared with the standard therapies alone, most of these
investigations reported no beneficial effect of Vit D in these
patients (Leyssens et al., 2013).
Effects of vitamin D on colon cancer cells
A consistent number of investigations provide evidence that
1,25(OH)2D3 and its semisynthetic analogues may play a key
role in the prevention and treatment of colorectal cancer
(Byers et al., 2012; Leyssens et al., 2013; Pereira et al., 2012).
Numerous studies have shown that colorectal cancer cells
express VDR and the enzyme 1a-hydroxylase that converts
25-hydroxyvitamin D3 [25(OH)D3] into the active metabolite
of vitamin D, 1,25(OH)2D3 (Matusiak et al., 2005). The
activation of VDR elicits antitumor effects by triggering
apoptosis and by inhibiting cell proliferation, invasion, and
angiogenesis (Gonza´lez-Sancho et al., 2006; Krishnan &
Feldman, 2011; Penda´s-Franco et al., 2008a; Samuel &
Sitirin, 2008). In particular, in vitro studies showed that this
molecule may inhibit the proliferation of colon tumor cells by
blocking the cell cycle in the G1 phase, by promoting
apoptosis and cell differentiation and by affecting tumor
angiogenesis (Bettoun et al., 2002; Pa´lmer et al., 2001;
Penda´s-Franco et al., 2008a; Pereira et al., 2012).
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Furthermore, on one hand, studies on different colon carcin-
oma cell lines showed that 1,25(OH)2D3 may promote
apoptosis by the up-regulation of the proapoptotic protein
BAK1 and the down-regulation of the nuclear anti-apoptotic
protein BAG1 and by preventing the formation of apoptotic
heterodimers Bcl-2-Bax (Pereira et al., 2012; Welsh, 2012).
The negative effects of 1,25(OH)2D3 on cell proliferation and
apoptosis are further underlined by the findings that this
molecule promotes sensitivity to the chemotherapeutic agent
5-fluorouracil (5-FU) by down-regulating the expression of
the anti-apoptotic protein survivin and that of thymidylate
synthase, a key enzyme in the biosynthethic pathway of DNA.
On the other hand, in vitro studies also reported that
1,25(OH)2D3 promotes cell differentiation by increasing the
expression of several components of cell adhesion that are
essential for the maintenance of the epithelial phenotype and
that of proteins associated with the actin cytoskeleton and
intermediate filaments (Pa´lmer et al., 2001; Pereira et al.,
2012). These findings are consistent with the observations
that the treatment of Caco-2 colon cancer cells with
1,25(OH)2D3 induced an increase in the expression of p21,
p27, E-cadherin, and other adhesion proteins (ZO-1, ZO-2,
and vinculin) and promotes the translocation of b-catenin and
ZO-1 from the nucleus to the plasma membrane (Gaschott
et al., 2002). More specifically, it was shown that the VDR
antagonist, ZK-191-732, modulates the differentiation process
induced by butyrate on Caco-2 cells (Gaschott et al., 2002).
Furthermore, it was established that a decrease in the levels of
cyclin D1 is essential for the anti-proliferative effects of Vit D
(Hofer et al., 1999; Maier et al., 2009). In vitro studies aimed
at assessing the effects of 1,25(OH)2D3 on the gene expres-
sion in SW480-ADH cell line showed that Vit D increased the
expression of c-Jun, JunD, Jund, FREAC-1/Fox1, ZNF-44/
Kox7, G0S2, tumor suppressors normal epithelial-cell-specific
gene 1 (NES-1), or kallikrein 10 and protease M (Pa´lmer et al.,
2003). This phenomenon further stresses the concept that Vit D
appears to play a role in cell growth inhibition, adhesion,
differentiation, and apoptosis. These effects ultimately lead to
the reversion of the neoplastic phenotype to a normal epithelial
phenotype (Gocek & Studzinski, 2009; Nagpal et al., 2005).
Finally, Meeker et al. (2014) by using a model of bacteria-
driven colitis and colon cancer when infected with
Helicobacter bilis (H. bilis) showed that mice fed high vitamin
D diet had a significantly lower incidence of cancer compared
with mice fed maintenance diet. These findings further suggest
that increased dietary vitamin D is beneficial in preventing
inflammation-associated colon cancer through the suppression
of inflammatory responses during the initiation of neoplasia or
early-stage carcinogenesis.
Colorectal cancer and vitamin D
Clinical studies
Colorectal cancer is the third most common type of cancer in
men and women in western countries (Chan & Giovannucci,
2010). There is strong evidence on a significant relationship
between lifestyle and diet and incidence-rate of this type of
cancer (Chan & Giovannucci, 2010). Several case–control
studies and cohort studies have examined the relationship
between Vit D intake (total, with diet, or supplementary) and
the risk of colorectal cancer (Giovannucci, 2010; Woolcott
et al., 2010). The consistent body of investigation that
analyzed the relationship between the serum 25-hydroxyvi-
tamin D3 [25(OH)D3] level and colorectal cancer risk
generally shows an inverse association (Freedman et al.,
2007). In support of these observations, a large observational-
nested case–control study undertaken within the European
Prospective Investigation into Cancer and Nutrition showed a
strong inverse association between 25(OH)D3 concentrations
and colorectal tumor (Jenab et al., 2010). Furthermore, a
recent meta-analysis of 35 independent studies further
confirmed the inverse relationship between circulating
levels of 25(OH)D3 and colorectal cancer risk (Gandini
et al., 2011; Maalmi et al., 2014). Finally, a systematic review
of 18 prospective studies carried out by Ma et al. (2011)
undertaken to assess the association of Vit D intake or 25-
hydroxyvitamin D3 serum levels and the risk of colorectal
tumor in about 1 000 000 individuals highlighted the fact that
vitamin D intake and 25-(OH)D3 blood levels were inversely
associated with the risk of colorectal cancer. In particular,
some of these studies showed that the intake of 1000 IU/d of
Vit D was associated with a 50% decrease in risk of colorectal
tumor, while plasma concentrations of 20–29 ng/ml of 25-
hydroxyvitamin D3 were associated with an increased risk of
developing colorectal cancer. Conversely, concentrations
higher than 30–39 ng/ml were associated with a decreased
risk (Jenab et al., 2010). However, some investigations have
reported different results. For instance, on one hand,
Wactawski-Wende et al. (2006) failed to show marked effects
of Vit D on the incidence of colorectal cancer. Furthermore,
the co-administration of calcium and Vit D in women taking
estrogen resulted in an increased risk of colorectal cancer. The
conclusion of the study was that Vit D supplementation may
have a greater impact on mortality, but a lower incidence of
colorectal cancer. On the other hand, Ishihara et al. (2008) did
not highlight any statistically significant correlation between
Vit D intake and risk of colorectal cancer. Only concentra-
tions of 25-(OH)D3 lower than 80 nmol/L were inversely
associated with mortality from colorectal cancer, but not with
the incidence. The discrepancies in these results were, in part,
explained by the fact that the subjects considered in these
studies were often taking food high in calories and low in
fiber. Moreover, these subjects did not carry out any physical
activity, had a high body mass index, a positive family history
of colorectal cancer, and were smokers. There was no
difference in the amount of Vit D and sunlight exposure
between cases and controls. The use of Vit D supplements
was more common among the controls, and this was
statistically significant among men. Because of these con-
flicting results further studies are needed to better define the
chemopreventive effects of Vit D on colorectal cancer.
Effects of vitamin D on SCC
The presence of VDR in keratinocytes and the ability Vit D
to induce differentiation and to inhibit cell proliferation may,
in part, account for the therapeutic potential of this molecule
and its semisynthetic analogues in the SCC of the head
neck (H&NSCC) and aerodigestive tract (Bikle, 2012;
Ma et al., 2013a,b; Nagpal et al., 2005). In particular, the
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inhibition of p21 expression in keratinocytes has been
reported to be an essential prerequisite for the induction of
cell differentiation (Di Cunto et al., 1998). 1,25(OH)2D3 has
been shown to inhibit SCC growth in vitro and in vivo
(Hershberger et al., 2001; Ma et al., 2013b). Interestingly,
recent in vitro studies have highlighted the additive inhibitory
effects of Vit D in combination with 5-FU and or 13-cis-
retinoic acid on human oral squamous carcinoma cell growth
(Dalirsani et al., 2012). In contrast, Gedlicka et al. (2006)
have shown that Vit D induced growth inhibition in SCC cell
lines of the head and neck by arresting cells in the G0/G1
phase of the cell cycle and that this effect was associated with
an upregulation of p18 cell-cycle inhibitor. Further studies
demonstrated that 1,25(OH)2D3 inhibits, in vitro, cell motility
and invasion of SCC cells while, in vivo, this molecule
markedly suppresses the ability of SCC cells to establish
pulmonary metastases in tumor-bearing mice (Ma et al.,
2013a). The potential target genes for Vit D have been
identified in cell line SCC25 following treatment with the
analogue EB1089 (Lin et al., 2002). The expression of genes
such as 24-hydroxylase, protease M, cystatin M, amphiregu-
lin, stromelysin, and collagenase I resulted up-regulated
whereas the expression levels of CRABP-II, N-cadherin, and
SCC antigen were down-regulated (Lin et al., 2002). The
effects of Vit D and its analogues on the expression of genes
involved in cell differentiation, growth inhibition, and
immunomodulation, further indicate that SCC cell lines can
be driven to differentiation by these compounds (Goceck &
Studzinski, 2009). To date, limited epidemiologic studies on
the effect of Vit D or its metabolites on SCC prevention or
treatment in humans have generated conflicting data.
Recently, Eide et al. (2011) reported a positive relationship
between plasma levels of 25(OH)D3 and non-melanoma skin
cancer (NMSC) including SCC and basal cell carcinoma
(BCC), in a study of 3223 white health maintenance
organization patients who sought advice about the risk of
osteoporosis or low bone density. These findings have been
confirmed by a recent nested case–control study among
women by Liang et al. (2012). Conversely, Tang et al. (2010)
highlighted higher serum 25(OH)D3 levels as being asso-
ciated with a decreased risk of NMSC in older Caucasian
men. The discrepancies in these results were explained by the
different observation periods and the different types of subject
enrolled in these studies. Overall, there is some evidence that
Vit D may be of clinical interest in SCC and melanoma
prevention. However, additional studies are needed to assess
the suitability of topical or oral Vit D for chemoprevention of
SCC and BCC in humans (Tang et al., 2012).
Effects of vitamin D on hematological malignancies
There is increasing interest in the possible use of Vit D to
combat hematological diseases including leukemias, myelo-
dysplastic syndrome (MDS), lymphomas, and multiple mye-
loma (MM) (Kim et al., 2012; Motomura et al., 1991; Shanafelt
et al., 2011). The potential therapeutic role of 1,25(OH)2D3
in the treatment of hematologic malignancies was first
highlighted by Abe et al. (2004) who reported that Vit D was
able to induce in vitro differentiation of M1 murine myeloid
cells. These findings were further confirmed by other
experimental in vivo studies which showed that the adminis-
tration of Vit D increased the survival time of mice inoculated
with leukemic cells (Honma et al., 1983). The possible
therapeutic effectiveness of 1,25(OH)2D3 in the clinical
treatment of hematological malignancies relies on the obser-
vations that this molecule appears to inhibit the proliferation of
hematopoietic precursor cells and to promote their maturation
and, ultimately, cell differentiation (Abe et al., 2004; Gocek &
Studzinski, 2009; Honma et al., 1983; Kim et al., 2012;
Shanafelt et al., 2011). The biochemical mechanisms through
which Vit D and its derivatives induce these effects have been,
only in part, elucidated (Kim et al., 2012). Experimental
observations have highlighted the fact that these mechanisms
may be different according to the cell type (Bhatia et al., 1995;
Hughes et al., 2010; Kim et al., 2012). For instance, Vit D may
induce monocytic differentiation of myeloid leukemia cells.
This phenomenon may result in the G1 phase cell-cycle block
and, consequently in the cessation of cell proliferation (Bhatia
et al., 1995). In acute promyelocitic leukemic cells, Vit D
appears to activate three types of intracellular signaling
pathways, namely PKC pathway, PI3K-AKT pathway, and
three different MAPK pathways which have been suggested to
intersect at a common nodal point (Raf-1) (Bhatia et al., 1995;
Goceck & Studzinski, 2009; Hughes et al., 2010; Kim et al.,
2012; Wang & Studzinski, 1997). Activation of the MAPK and
PI3K-AKT pathways has also been implicated in Vit D-
mediated VDR synthesis and nuclear translocation (Goceck &
Studzinski, 2009; Kim et al., 2012). However, in the acute
promyelocytic leukemia cell line NB4, the monocytic differ-
entiation was induced independently of any VDR/VDRE
interaction (Bhatia et al., 1996). On the other hand, in U937
leukemic cells, Vit D was shown to activate the transcription of
cycline-dependent kinase inhibitors p21Waf1/Cip1 and
p27Kip1 and that of the protein HOXA10 (Liu et al., 2010).
Overexpression of p21 and HOXA10 facilitates the differen-
tiation of U937 cells into monocytes/macrophages cell lineage
(Kim et al., 2012; Rots et al., 1998). Therefore, the therapeutic
strategies currently available in the clinical treatment of
leukemias and MDS include agents that induce differentiation
of hematopoietic precursors (Harrison & Bershadskiy, 2012;
Kim et al., 2012; Nagpal et al., 2005; Shanafelt et al., 2011).
The main hematologic responses were observed in patients
with MDS treated with calcitriol and alfacalcidol (Kim et al.,
2012; Mellibovsky et al., 1998). Although the range of
response in these studies varied from 44 to 100%, with
complete remission in only 6% of patients, the prevention of
the progression of MDS is significant. Recent findings have
shown that Vit D may induce antileukemic effects by
promoting autophagy in leukemic cells via the increase of
the intracellular levels of beclin-1 which is known to induce
the formation of autophagosomes in mammalian systems
(Kim et al., 2012; Wang et al., 2008). On the contrary, in the
K562 chronic myeloid leukemia cell line, which is character-
ized by a rapid growth rate and lack of differentiation, Vit D
was found to induce apoptosis (Kim et al., 2012; Wang &
Studzinski, 1997). Similarly, the treatment of HL-60 cells with
Vit D induced an increase in Mcl-1, an anti-apoptotic protein
that blocks cytochrome c release in the apoptosis pathway and
may also target Raf-1 (Kim et al., 2012; Wang & Studzinski,
1997). Although experimental studies support a potential
18 M. Giammanco et al. Pharm Biol, Early Online: 1–36
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clinical benefit of the use of Vit D derivatives in the treatment
of hematological malignancies, the partial validation observed
in clinical trials against acute myeloid leukemia and MDS
implies that the therapeutic effectiveness of Vit D in these
malignancies deserves further extensive investigation (Kim
et al., 2012).
Effects of cancer on vitamin D metabolism
Effects of cancer on VDR levels
Although a consistent body of experimental and clinical
research have been undertaken in order to define the
therapeutic effectiveness of Vit D on cancer, other studies
have been directed towards investigating the impact of cancer
on the Vit D system. Some of these studies have shown that
VDR may be overexpressed or down-regulated in various
human cancers (Friedrich et al., 2006; Kure et al., 2009;
Lopes et al., 2012; Motomura et al., 1991; Matusiak et al.,
2005; Reichrath et al., 2004). For instance, Matusiak et al.
(2005) demonstrated that the expression levels of VDR were
low in normal epithelial cells of the colon while they were
increased in aberrant crypts foci, in polyps, and in well-
differentiated cancer cells. These findings are in line with
those of Kure et al. (2009) who showed that in 233 out of 619
patients the overexpression of VDR was associated with
mutations of Ras-MAPK and PI3K-AKT. Conversely, clinical
studies in 82 patients with melanoma highlighted a remark-
able reduction, or even the absence, of VDR expression in
tumor tissue in comparison with normal skin. This phenom-
enon was correlated with the progression of melanocytic
lesions (Broz_yna et al., 2011). These data suggest that altered
expression levels of VDR may be regarded as a potentially
useful marker in the follow-up of melanoma patients treated
with Vit D or its semisynthetic analogues. Furthermore,
studies undertaken to assess the expression level of VDRs in
normal mammary cells, in benign lesions, in localized breast
cancer, and invasive breast cancer highlighted the presence of
these receptors in a variety of breast tissues with some
quantitative differences (Lopes et al., 2010; Zhang et al.,
2014). In particular, VDRs were frequently expressed in
benign lesions (93.5%) while in carcinoma in situ or in
metastatic tumor the rate of expression was lower (56.2%)
(Lopes et al., 2010). Similar results were obtained from
studies which evaluated the expression level of VDR in
benign and malignant ovarian tissues (Thill et al., 2010).
These studies showed that VDR expression levels were
significantly lower in malignant tissue as compared with
normal tissue. On one hand, it is worth noting that Zhang
et al. (2014) recently demonstrated a negative correlation
between VDR expression in human breast cancer tissue and
metastasis in breast cancer. Furthermore, coculture of VDR-
overexpressing breast cancer cells with a macrophage cell line
demonstrated that overexpression of VDR alleviated the
prometastatic effect of cocultured macrophages on breast
cancer cells. On the other hand, Hendrickson et al. (2011),
by assessing the level of expression of VDR in tumor tissue
from 841 patients with prostate cancer, showed that the
high expression of VDR in tumor tissue was associated with
a reduced risk of cancer death suggesting an important role
of Vit D on prostate cancer progression. Interestingly,
Srinivasan et al. (2011) recently described the presence of
VDR at nuclear and cytoplasmic levels in lung cancer cells.
These authors additionally showed that while the high levels
of nuclear VDR were associated with increased survival, no
correlation was observed between the survival and the
expression levels of cytoplasmic VDR. Furthermore, it has
been reported that some gene mutations are strongly
associated to cancer progression such as observed in the
case of Ha-Ras, in HC-11 mouse mammary epithelial cells
(Escaleira & Brentani, 1999) or K-Ras in RWPE-2 cells
(Zhang et al., 2010) or Simian Virus 40 (SV40) in human
mammary epithelial (HME) cells (Kemmis & Welsh, 2008),
and that this phenomenon may result in a decreased
expression of VDR. On the other hand, several studies have
identified many factors that may influence the expression of
VDR in cancer. For instance, it has been shown that the
overexpression of SNAIL transcription factors can reduce the
expression of the gene encoding VDR in SW-480-ADH,
HCT116, Caco-2, LS174T, and HT29 colon cancer cell lines
(Pa´lmer et al., 2004). Furthermore, Larriba et al. (2013)
showed that SNAIL1 repressed the expression of VDR and
also inhibited the migration of nuclear b-catenin induced by
1,25(OH)2D3 in SW-480-ADH colon cancer cells. In addition,
SNAIL1 thwarted the inhibitory effects of 1,25(OH)2D3 on
cell proliferation. In colon and breast cancer cell lines,
SNAIL1 and SNAIL2 can bind E-boxes in the proximal
promoter of the gene for VDR and enhance the recruitment of
co-repressors that reduce the expression of VDR (Mittal et al.,
2008; Pen˜a et al., 2005). Another protein that regulates the
expression of VDR gene is p53. It has been shown that in
Saos-2 osteosarcoma cells and human non-small cell lung
cancer cells H1299, the overexpression of p53, resulted in an
increased expression of VDR (Maruyama et al., 2006).
Unfortunately, p53 gene is mutated in many human tumors
and this may account for the reduced expression of VDR gene
in breast and lung cancer cells. Interestingly, the p53 mutant
form has been shown to be able to interact with VDR, to
increase its accumulation in the nucleus, and to convert Vit D
into an antiapoptotic agent (Stambolsky et al., 2010). These
findings indicate that in tumors with p53 mutant, the
therapeutic potential of Vit D or its analogues may be limited
(Stambolsky et al., 2010). In addition, there is also some
evidence that ras activation can decrease the transcriptional
activity mediated by Vit D (Fleet et al., 2012). This
phenomenon was first described by Solomon et al. (1999),
who observed that in ras-transformed keratinocytes, the
transcriptional activity mediated by VDRs was reduced as a
result of phosphorylation on serine 260 of the heterodimeric
partners of the VDR, namely RXR. A reduction in the
transcriptional activity of the VDR after phosphorylation
within the domain of RXR AF-1 was also observed in the
RWPE2 cell line (Zhang et al., 2010). Overall, these studies
suggest that the development of cancer can lead to a reduction
of the responses mediated from 1,25(OH)2D3 thus weakening
VDR-mediated signaling pathways.
Effects of malignant transformation on
1-a-hydroxylase (CYP27B1) expression levels
Although the presence of the enzyme 1-a-hydroxylase, in
many tumor tissues, has been well recognized, studies on the
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expression of this enzyme during cancer development have
had discrepant results (Cross et al., 2005, 2009; Ho¨baus et al.,
2013). In fact, the expression and activity of CYP27B1 have
been shown to increase, decrease, or remain unchanged
according to the organ, the tumor grade, and the reference
tissue (Cross et al., 2005; Ho¨baus et al., 2013). In this context,
several in vitro studies have shown that the activity of
CYP27B1 and its contribution to 1,25(OH)2D3 production is
lost in tumors with an aggressive phenotype (Fleet et al.,
2012). On the other hand, Hsu et al. (2011) reported that
CYP27B1 was present in normal prostate epithelia cells
(PECs). However, its enzyme activity was reduced in cells
isolated from BPH while it was virtually absent in cells
isolated from prostate cancer patients. Further, Segersten
et al. (2002) reported that this enzyme was overexpressed in a
number of parathyroid adenomas of primary hyperthyroidism
(HTP) and in hyperplastic glands of secondary HPT while it
resulted underexpressed in parathyroid carcinomas, compared
with normal parathyroid glands. These findings are consistent
with the observations that, unlike cancer cells, normal cells
were susceptible to the growth inhibiting effects of
1,25(OH)2D3 treatments. These results were confirmed by
another study which showed that the reduced expression of
CYP27B1 in LNCaP cells resulted in a reduced growth
inhibition induced by 1,25(OH)2D3 (Chen et al., 2003).
Moreover, CYP27B1 expression was undetectable in metas-
tases from human colon cancer (Matusiak & Benya, 2007).
More recently, Broz_yna et al. (2011) showed an inverse
correlation between CYP27B1 expression levels and melan-
oma progression. However, the relationship between
decreased levels of CYP27B1 and malignant phenotype was
not univocally observed in all types of cancer (Fleet et al.,
2012). For instance, Friedrich et al. (2006) showed that the
mRNA coding for CYP27B1 increased in breast cancer when
compared with normal tissue. Furthermore, Clinckspoor et al.
(2012) recently highlighted CYP27B1 expression levels as
increasing in malignant thyroid tumors. Conversely, immu-
nohistochemical observations by Lopes et al. (2010, 2012)
failed to highlight significant differences in the expression of
CYP27B1 between normal breast tissue and tumor tissue
while discrepant results were obtained with renal carcinoma
(Blomberg Jensen et al., 2010; Urbschat et al., 2013). Because
of these conflicting data, no definitive conclusion can be
drawn on the consequences of malignant transformation on
the expression of CYP27B1.
Effects of malignant transformation on
24-hydroxylase (CYP24A1) expression levels
Similarly, as described for CYP27B1, the level of
CYP24A1 expression, an enzyme involved in the degradation
of metabolic products of Vit D, may be influenced by the
malignant transformation (Cross et al., 2011; Hobaus et al.,
2013). In fact, aberrantly high basal expressions of CYP24A1
have been observed in various tumors (Hobaus et al., 2013;
Horva´th et al., 2010). Furthermore, epidemiological studies
showed that serum levels of 25(OH)D3, the precursor of
1,25(OH)2D3, below 30 nM were strongly associated with an
increased incidence of colorectal cancer (Cross et al., 2011).
In this context, recent experimental and clinical observations
by Cross et al. (2005) and Brozek et al. (2012) reported that
the expression levels of CYP24A1 increased dramatically
during colorectal cancer progression to a poorly differentiated
stage (G3–G4). Furthermore, studies on breast cancer showed
that the CYP24A1 gene was overexpressed in this type of
tumor and that this phenomenon also accounted for the
inhibition of the antiproliferative effects of 1,25-(OH)2D3 on
tumor cells (Lopes et al., 2010). Consistent with these
observations, Anderson et al. (2006) reported an increased
expression of CYP24A1 levels in MCF-7, SW-620 breast
cancer cells, in breast tumor tissue and in ovary, colon, and
lung cancer. Subsequent studies showed that CYP24A1 was
present in the nuclei of normal colonic epithelial cells,
aberrant cryptic foci and adenomatous polyps (Matusiak &
Benya, 2007). However, following malignant transformation,
the location of this enzyme shifted almost entirely from the
nuclear compartment to the cytoplasmic compartment
(Matusiak & Benya, 2007). Overexpression of CYP24A1
was also demonstrated in prostate cancer, ovarian cancer,
cervical cancer, lung cancer, SCC, and BCC (Friedrich et al.,
2006; Mitschele et al., 2004; Muindi et al., 2007). In
esophageal cancer, high CYP24A1 expression was reported
to correlate with a poor prognosis (Mimori et al., 2004).
Overall, these data highlight the altered metabolism of 1,25-
(OH)2D3 as appearing to be a typical feature of advanced
cancer and also suggest that one major mechanism respon-
sible for Vit D resistance or reduced sensitivity to calcitriol in
VDR-positive cells may be dependent on an increase of 1,25-
(OH)2D3 and 25(OH)D3, catabolism via the C-24 hydroxyl-
ation pathway. In line with these observations, Muindi et al.
(2007) have demonstrated that ketoconazole, an inhibitor of
CYP24A1, can restore the activity of growth inhibition
exerted by 1,25-(OH)2D3 in prostate cancer cells. More
recently, Komagata et al. (2009) found that the levels of
CYP24A1 can be reduced at post-transcriptional levels by
miR125b, a micro-RNA that can bind the 30-UTR (untrans-
lated region) mRNA for CYP24A1. In addition, these authors
demonstrated that, in breast cancer, CYP24A1 levels were
inversely related to miR125b levels suggesting that the lack of
this regulatory RNA may account for the increased expression
levels of CYP24A1 in cancer cells. These findings might, in
part, account for the limited therapeutic effects of
1,25(OH)2D3 observed in some clinical trials. Thus the
inhibition of CYP24A1 by pharmacological means may lead
to a new approach in Vit D-based treatment of neoplastic
diseases.
The semi-synthetic analogues of Vit D
The numerous epidemiological and preclinical investigations
suggesting a role of Vit D in the prevention and treatment of
several human tumors support the clinical use of
1a,25(OH)2D3 and Vit D analogues as potential preventive
and therapeutic anticancer agents (Brown & Slatopolsky,
2008; Trump et al., 2010). However, the hypercalcemic
effects induced by 1,25(OH)2D3 have strongly limited its
therapeutic use (Ma et al., 2010; Mehta, 2012). Therefore,
many efforts are currently being directed towards synthesizing
new Vit D analogues with the goal of improving the
biological profile of the natural hormone, which retains the
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therapeutic activity the analogues being endowed with a lower
calcemic effect (Byers et al., 2012; Chen & Kittaka, 2011;
Fleet et al., 2012; Trump et al., 2010). Vit D analogues are
semi-synthetic molecules, since they share the basic structure
of 1,25(OH)2D3 but differ in the presence of a characteristic
functional group (R) (Brown & Slatopolsky, 2008; Trump
et al., 2010; Unten et al., 2004) (Figure 2). To date, nearly
1500 Vit D analogues have been synthesized and evaluated,
in vitro and in vivo, for their therapeutic effectiveness, in a
variety of carcinogenesis and human cancer models (Leyssens
et al., 2014; Mehta, 2012). However, of these compounds,
only a few have been approved for further evaluation in
clinical trials in leukemia patients, breast cancer patients,
prostate cancer patients, and colon cancer patients (Agoston
et al., 2006; Hussain et al., 2003; Kim et al., 2012; Leyssens
et al., 2014; Mehta, 2012). The chemical structure of some of
the Vit D analogues endowed with cancer chemo-preventive
activity is shown in Figure 2. Analogues that are structurally
unrelated to Vit D but are able to interact with VDR have also
been synthesized (Byers et al., 2012; Choi & Makishima,
2009). More recently a new class of Vit D analogues,
characterized by two side-chains linked to carbon-20
(Gemini) and with deuterium substituted on one side-chain,
have been synthesized (Maehr et al., 2013; Okamoto et al.,
2014; Spina et al., 2007). Although these analogs do not show
any adverse calcemic effects from Vit D, they may induce
other toxic effects unrelated to calcemia (Mehta et al., 2012).
Alfacalcidol and doxercalciferol
Alfacalcidol (1a,25(OH)D3) and doxercalciferol (1a,25OHD2)
(Figure 2) are Vit D analogues endowed with chemopreventive
effects. Early reports from Iseki et al. (1999) showed that a
long-term administration of high doses of alfacalcidol signifi-
cantly reduced the incidence of colon cancer in rats. In line
with these observations, Kikuchi et al. (2007) showed that
treatment with alfacalcidol prevented the ulcerative colitis
and the development of colon cancer in mice. Similar results
were reported from experiments on female Sprague–Dawley
rats with 7,12-dimethylbenz[a]anthracene(DMBA)-induced
mammary tumor where the administration of alfacalcidol
suppressed the growth of tumors in a dose-dependent fashion
(Iino et al., 1992). Hara et al. (2001) showed that the oral
administration of alfacalcidol to mice transplanted with Dunn
osteosarcoma significantly suppressed tumor growth and
metastasis formation. The same study reported that the co-
Figure 2. The chemical structure of Vitamin D analogues endowed with cancer chemo-preventive activity.
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administration of alfacalcidol and doxorubicin resulted in
additive antitumor and antimetastatic effects. Although the
mechanisms of the antitumor effects of alfacalcidol have not
yet been fully elucidated, experimental evidence indicates that,
in particular, this molecule may inhibit tumor angiogenesis
(Iseki et al., 1999). These findings suggest that alfacalcidol
might be of therapeutic value as a chemopreventive agent in the
clinical management of cancer patients. Consistent with these
results, clinical studies by Tałalaj et al. (2005) reported that, in
patients with advanced prostatic carcinoma treated with
complete androgenic blockade, the administration of alfacal-
cidol and calcium supplement (CaCO3) prevented both
trabecular and compact bone loss. On one hand, more recent
clinical observations by Obara et al. (2008) have highlighted
the fact that in Japanese patients with metastatic renal
carcinoma (RCC), the combination of alfacalcidol and inter-
feron-a may prolong the survival of these patients without
causing severe adverse events. On the other hand, Trouillas
et al. (2001) showed that alfacalcidol may induce in some
patients, in synergy with classical surgery–radiotherapy–
chemotherapy treatment, a particular progressive and durable
regression of the tumor. Cunningham et al. (1985) reported that
the administration of alfacalcidol induced a partial remission in
patients with lymphoma. On one hand, more recently Akiyama
et al. (2010) showed that the addition of alfacalcidol to Vitamin
K appears to improve anemia and thrombocytopenia in about
one-third of patients with low/intermediate-1 MDS who had
not responded to Vitamin K2 monotherapy for 16 weeks. On
the other hand, recent findings by van Ginkel et al. (2007) show
that doxercalciferol can inhibit human neuroblastoma growth
in vivo with relatively low toxicity. However, recent clinical
investigation by Gee et al. (2013) reported no obvious
beneficial effects in men undergoing prostatectomy for early-
stage prostatic neoplasia, while Petrich et al. (2008) showed
that a short-term treatment with doxercalciferol has limited
activity in patients with MDS. These conflicting results
suggest that further clinical studies are needed to better
define the clinical effectiveness of this molecule in cancer
chemoprevention.
Calcipotriol
Calcipotriol, or calcipotriene (Figure 2), is a synthetic Vit D
analogue that exhibits a vitamin D-like effect by competing
for VDR displaying minimal effects on calcium homeostasis
(Binderup & Bramm, 1988). The intraperitoneal or oral
administration of calcipotriol to rats showed that the
compound was at least 100 times less active than
1,25(OH)2D3 in determining hypercalcemia and hypercal-
ciuria (Binderup & Bramm, 1988; Kissmeyer & Binderup,
1991). Experimental observations show that this molecule
exerts important effects on cellular differentiation and prolif-
eration in vitro while its effect on calcium metabolism in vivo
is negligible (Binderup & Bramm, 1988; Cho et al., 1996).
In vitro studies showed that this molecule may regulate cell
differentiation and proliferation and exhibits growth-inhibit-
ing effects against several human cancer cell lines including
HL-60 and HL60/MX2 promyelocytic leukemia, U937
histiocytic lymphoma, MCF-7, T47D human breast cancer,
HT-29 human colon cancer, and human SCC (Colston et al.,
1992; Meephansan et al., 2012; Milczarek et al., 2013a,
2014). Regarding the possible mechanisms underlying the
growth inhibiting and pro-differentiating effects of calcipo-
triol on tumor cells, in vitro studies highlighted the fact that a
20-h exposure of LNCaP prostate cancer cells and MCF-7
breast cancer cells to this analogue or to BGP-15, a new
calcipotriene-derived vitamin D3 analogue, generated procas-
pase-3 cleavage and ultimately, apoptosis (Berkovic et al.,
2010). In addition, Wang et al. (2010b) recently reported that
calcipotriol significantly suppressed in vitro colon carcinoma
cell invasion and enhanced the cytotoxicity of the anticancer
regimen FOLFIRI (folinic acid, 5-FU, irinotecan) to cells in
culture or in anchorage-independent growth. These effects
appeared to be the consequence of a suppression of gene
transcriptional activities and protein expression of survivin
and thymidylate synthase, to the enhanced E-cadherin local-
ization in cell membranes and the complex formation of E-
cadherin and b-catenin, and repression TCF4 transcriptional
activation. Consistent with these observations, on one hand,
recent findings by Milczarek et al. (2014) showed that
calcipotriol may potentiate the antitumor activity of 5-FU in
HT-29 colon tumor-bearing mice. These studies also showed
that the mechanism of potentiation of 5-FU antitumor was
related to the increased expression of p21 and decreased
expression of pERK1/2 level which may lead to a decreased
expression of thymidylate synthase. On the other hand,
Meephansan et al. (2012) highlighted the fact that calcipotriol
affects in vitro the invasive potential of DJM human
squamous carcinoma cells by reducing the production of
matrix-metalloproteinases MMP-9 and MMP-13 through
inhibition of the ERK and p38 phosphorylation. The
antitumor activity of calcipotriol was also investigated
in vivo using rats transplanted with breast cancer induced
by N-methyl-nitrosourea (Colston et al., 1992a). These studies
showed how the administration of calcipotriol (50 mg/kg)
resulted in an inhibition of tumor progression without
development of severe hypercalcemia. On one hand, more
recent in vivo investigation by Pommergaard et al. (2013)
demonstrated that in mice with UVB-induced non-melanoma
skin cancer (NMSC), the topical treatment with calcipotriol
combined with diclofenac and difluoromethylornithine for
17 weeks significantly reduced the number of mice with
tumors as well as tumor area size compared with placebo.
On the other hand, early clinical studies reported that in 15
out of 19 patients with localized breast cancer or skin
metastases, the topical treatment with calcipotriol (100 mg/d
for 6 weeks) caused a reduction of 65% of the diameter of
the lesions, a reduction of 50%, in 3/19 patients while one
patient showed a minimal response (Bower et al., 1991). It is
worth noting that only two patients developed hypercalcemia
during treatment. Interestingly, recent observations by Al-
Jaderi and Maghazachi (2013) suggested that calcipotriol
may influence the activity of cells of the innate immune
system. In fact, these authors showed that calcipotriol may
increase IL-2-activated NK cell lysis of K562 and RAJI
tumor cell lines as well as immature and mature dendritic
cells and may down-regulate the expression of the killer
inhibitory receptor CD158. These findings make calcipotriol
of potential interest as another novel chemopreventive agent
in cancer treatment.
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Maxacalcitol (22-oxa-1a,25-D3)
Maxacalcitol (1a,25-dihydroxy-22-oxacalcitriol) (OCT)
(Figure 2) is another non-calcemic Vit D analogue and
VDR ligand that has been shown to promote cell differenti-
ation and to inhibit cell proliferation, without inducing
hypercalcemia (Abe et al., 1991; Nishii & Okano, 2001;
Funato et al., 2002). This molecule contains an oxygen in
place of a carbon in position 22 of the side chain (Figure 2)
and is less calcemic than 1,25(OH)2D3. However, it retains
considerable potency to suppress PTH in vitro and in vivo
(Nishii & Okano, 2001). In vitro studies show that
maxacalcitol could block the G1/S transition and induce
tumor cell growth inhibition in responsive pancreatic tumor
cells (Kawa et al., 2005). The antiproliferative effect of
maxacalcitol on these cells appears to be due to the up-
regulation of p21 and p27 induced by this molecule (Kawa
et al., 2005). Interestingly, Funato et al. (2002) also report that
the co-administration of OTC with Vitamin K2 induces an
accumulation of the cells in the G0/G1 phase but suppresses
apoptosis. The growth inhibitory effects of 22-oxa-calcitriol
were also reported in breast cancer cells. In fact, in vitro
studies showed that this molecule inhibited, in a dose- and
time-dependent fashion, the proliferation of ER(+) breast
cancer cells (MCF-7, T-47D, and ZR-75-1) and ER() breast
cancer cells (MDA-MB-231 and BT-20) (Abe et al., 1991). In
line with these findings, in vivo studies on athymic mice
transplanted with MCF-7/ER(+) or MX-1/ER() breast cancer
cells showed that the administration of OCT elicited a potent
antitumor effect in both ER(+) and ER() tumor cells (Abe-
Hashimoto et al., 1993). These studies also demonstrated that
the degree of therapeutic effectiveness of OCT was compar-
able with that of tamoxifen in ER(+) tumors or to that of
adriamycin in ER() tumors. Furthermore, in MCF7/ER(+)
tumors, the co-administration of OCT and tamoxifen resulted
in a synergistic antitumor effect (Abe et al., 1991; Abe-
Hashimoto et al., 1993). Interestingly, on one hand, other
in vivo studies reported that in mice transplanted intraven-
ously with Lewis Lung Carcinoma cells (LLC), the admin-
istration of OTC was highly effective in reducing lung
metastasis formation (Nakagawa et al., 2005). These authors
suggested that this effect was likely related to ability of this
compound to affect tumor-induced angiogenesis in vitro and
in vivo (Nakagawa et al., 2005). On the other hand, the results
of these studies are consistent with those of Matsumoto et al.
(1999) reporting that the administration of OTC to mice
transplanted with MDA-MB-231 ER() human breast cancer
cells partially suppresses tumor growth by inhibiting the
expression levels of the vascular endothelial growth factor
(VEGF) and, ultimately, tumor neovascularization. More
recent observations by Seubwai et al. (2010) showed that
OTC effectively suppressed the growth of cholangiocarci-
noma (CCA) cell lines in a time-dependent and dose-
dependent manner by blocking tumor cells in the G1 phase
of the cell cycle and the transition of CCA cells from G1 to S
phase by suppressing or up-regulating the expression of
genes, i.e., cyclin D1 and p21, respectively, which regulate
this transition. Moreover, supplementation of OTC to CCA-
inoculated NOD/Scid/Jak3-deficient mice (NOJ) significantly
inhibited tumor growth without hypercalcemia or other
serious side effects. This treatment also induced cellular
apoptosis in tissue samples from patients with CCA. The
effects of maxacalcitol were also investigated in rats treated
with five carcinogens (Otoshi et al., 1995). In this study, 25
rats were administered intraperitoneally with maxacalcitol
(30 mg/kg), three times a week for 24 weeks from the initial
exposure to carcinogens. At the end of a 30-week observation
period, none of the rats that had received maxacalcitol after
the carcinogens developed cancerous lesions in the small
intestine while the incidence was higher in control animals.
The incidence of colon carcinoma in the group that received
only maxacalcitol showed a great tendency to decrease
(Otoshi et al., 1995). These studies, although not clarifying
the mechanisms of action, suggest that the maxacalcitol may
be of potential clinical value in the prevention of breast cancer
and colorectal cancer.
EB1089 (seocalcitol)
EB1089, also known as seocalcitol (Figure 2), is a Vit D
analogue which has been shown to inhibit either in vitro or
in vivo the growth of several types of tumor such as breast
cancer (Colston et al., 1992a; Macejova´ et al., 2011; Valrance
et al., 2007; VanWeelden et al., 1998), prostate cancer (Bhatia
et al., 2009; Chen et al., 2003; Oades et al., 2002), colon
cancer (Akhter et al., 1997; Oh et al., 2001), and
hepatocellular carcinoma (Ghous et al., 2008; Zhang et al.,
2013). In vitro observations showed that EB1089 was more
effective than 1,25(OH)2D3 in inhibiting the cell proliferation
of MCF-7 breast cancer cells (VanWeelden et al., 1998).
In vivo, the antitumor effects of EB1089 were investigated in
rats with mammary cancer induced by N-methyl-nitrosourea
(Colston et al., 1992) orally administered with two different
dose levels. The administration of the lower dose resulted in a
significant inhibition of tumor growth while, an equivalent
dose of 1,25(OH)2D3 had no effect on tumor growth but
induced hypercalcemia. Conversely, at the higher dose,
EB1089 determined tumor regression. In addition, on one
hand, experimental evidence showed that the combination of
EB1089 with cytotoxic agents and/or ionizing radiation
resulted in additive antitumor effects on breast cancer tumor
cells either in vitro or in vivo (Demasters et al., 2006;
Koshizuka et al., 1999; Sundaram et al., 2003; Valrance et al.,
2007). On the other hand, Oades et al. (2002) showed that
EB1089 also inhibited the growth of prostate adenocarcinoma
in the Dunning prostate model and in athymic nude mice
transplanted with LNCaP. Similar effects were recently
reported in an in vivo study by Bhatia et al. (2009). These
authors showed that EB1089 inhibited prostate cancer cell
proliferation and reduced tumorigenesis as well as tumor
metastases. Furthermore, in vitro studies on U937 histiocytic
lymphoma cells showed that EB1089 was 50–100 times more
effective in inhibiting cell proliferation and in inducing cell
differentiation than 1,25(OH)2D3 but less effective than
calcitriol in affecting in vivo calcium metabolism in rats
(Mathiasen et al., 1993). These data match those reported by
Gulliford et al. (1998) showing that EB1089 was significantly
less calcemic than 1,25-dihydroxyvitamin D3 when adminis-
tered at a maximum-tolerated dose (7 mg/m2) to patients with
breast cancer or colorectal cancer. Other in vitro observations
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on HT-29 colon adenocarcinoma cells showed that EB1089
was more effective than Vit D in inhibiting HT-29 prolifer-
ation (Oh et al., 2001). In particular, immunoblot analysis
showed that EB1089 inhibited the secretion of IGF-2 and
stimulated the production IGFBP-6. More recently Lu et al.
(2008) reported that EB1089 inhibits the proliferation of Hep-
2 human laryngeal squamous carcinoma cells. The growth-
inhibiting activity of this molecule appeared to be due to an
increase of p57 cyclin-dependent kinase inhibitor at mRNA
and protein levels induced by this molecule. EB1089 brought
about tumor cell death by a mechanism, not related to caspase
activation, which consisted in the induction of chromatin
condensation and DNA fragmentation (Høyer-Hansen et al.,
2005). Furthermore, recent findings by Ghous et al. (2008)
showed that EB1089 may inhibit either in vitro or in vivo the
growth of hepatocellular carcinoma (HCC). Interestingly,
Zhang et al. (2013) recently reported that a combination of
retinoic acid (RA) and EB1089 exerted a synergistic growth
inhibition and apoptosis induction in HCC cells. Furthermore,
in vivo studies carried out in rats with prostate cancer showed
that the administration of EB1089 decreased the tumor size
and the number of lung metastases (Chen et al., 2003).
Although these experimental observations are encouraging,
clinical studies aimed at evaluating the therapeutic effective-
ness of this molecule in cancer patients have generated
controversial results. In particular, phase I and II studies in
patients with breast cancer, colorectal cancer, hepatocellular
carcinoma, or pancreatic cancer failed to demonstrate any
therapeutic response of patients to EB1089 treatment (Dalhoff
et al., 2003; Evans et al., 2002; Gulliford et al., 1998).
However, it cannot be ruled out that patients’ characteristics
(i.e., presence/absence of VDR in tumor tissue, previous
treatments, low number of enrolled patients, dose-limiting
hypercalcemia, etc.) might, in part, account for this phenom-
enon. Therefore, further studies are needed to better define
the potential clinical effectiveness and toxicity of EB1089.
Analogues of 20-epi vitamin D
The 20-epi-vitamin D3 analogues including CB-1093, KH-
1060 (lexicalcitol), BXL-628 (elocalcitol), and 2MD are
molecules characterized by an altered stereochemistry at
carbon 20 in the side-chain (Binderup et al., 1991) (Figure 2).
These molecules except 2MD (2-methylene-19-nor-(20S)-1-
,25(OH)2D3) have been shown to possess chemopreventive
activity. 2MD has been shown to stimulate bone formation
in vivo and in vitro (Ke et al., 2005; Ma¨enpa¨a¨ et al., 2001) but
it appears to be devoid of antitumor activity (Ke et al., 2005).
Therefore, this compound has been proposed for the treatment
of osteoporosis (Plum et al., 2006). In vitro observation
showed that KH1060 and CB1093 may inhibit cell prolifer-
ation, at lower concentrations and earlier points in time than
calcitriol, by blocking the cell cycle in the G0/G1 phase
(Ma¨enpa¨a¨ et al., 2001; Ryha¨nen et al., 2003). This phenom-
enon appeared to be the consequence of an increase in the p27
level and a marked decrease of Cdk2. These phenomena
ultimately contribute to keeping retinoblastoma (Rb) protein
in its hypophosphorylated, i.e., growth suppressing, form thus
preventing cell-cycle progression through the restriction point
(Elstner et al., 1999; Ma¨enpa¨a¨ et al., 2001; Ryha¨nen et al.,
2003). These data are consistent with other in vitro studies
showing that CB1093 and KH1060, alone or in combination
with 9-cis-retinoic acid, inhibited the growth of LNCaP
human prostate cancer cells (Elstner et al., 1999) and human
neuroblastoma cells (Gumireddy et al., 2003). It was also
demonstrated that these effects were associated with increased
levels of p21(waf-1) and p27(kip1) protein. The inhibiting
effects of CB1093 on the growth of prostate adenocarcinoma
was also confirmed in vivo by some experimental studies
showing that this analogue inhibited tumor growth in the
Dunning prostate model and in athymic nude mice trans-
planted with LNCaP tumor cells (Oades et al., 2002). Other
studies, performed on MCF-7, T47D, and Hs578T breast
cancer cell lines, showed that CB1093 enhanced the response
of breast cancer cells to TNF-a and the intracellular
production of ceramide which appeared to act as downstream
effectors in Vit D-mediated caspase-independent cell death
(Mathiasen et al., 1993; Pirianov & Colston, 2001).
Interestingly, Danielsson et al. (1998) reported that CB1093
appeared to be very effective in inducing apoptosis in the
early stage in the WM1341 melanoma cell line, but not in the
advanced stage in MeWo melanoma cell line. Other studies
examined the effects induced by BXL-628 analogue or
Elocalcitol in benign prostatic hyperplasia and in prostate
cancer cells (Adorini et al., 2007; Penna et al., 2009; Tiwari,
2009). The results of these studies indicated that the main
mechanism appears to be related to the inhibition of growth
factors and to the interleukin-8 (IL-8) production via a
decrease in COX-2 and PGE2 synthesis (Adorini et al., 2007;
Penna et al., 2009). Elocalcitol was also able to inhibit the
proliferation and invasiveness of prostate cancer cell line,
DU145 by interfering with keratinocytes growth factor
(KGF)-induced proliferation (Marchiani et al., 2006). Based
on these results, these molecules may be of potential clinical
interest as novel chemopreventive agents. Further clinical
studies may better assess their clinical effectiveness in cancer
prevention and treatment.
Tacalcitol and eldecalcitol
Tacalcitol (1,24-dihydroxyvitamin D3, PRI-2191) is an active
metabolite of 1a,25(OH)2D3 (Figure 2) that does not exhibit
the high calcemic activity of the original compound
(Wietrzyk et al., 2004). Studies aimed at assessing the
antitumor activity and toxicity of tacalcitol showed a lower
toxicity of this molecule after its subcutaneous administration
compared with that of calcitriol (Wietrzyk et al., 2004).
Furthermore, the oral administration of tacalcitol increased
calcium serum levels by 47%, while calcitriol increased
these levels by 78%. Interestingly, the treatment of mice with
breast cancer with tacalcitol caused a reduction of the tumor
volume by 41% (Wietrzyk et al., 2004). Moreover, the
co-administration of tacalcitol with antitumor drugs such as 5-
FU and cisplatin or oxaliplatin and irinotecan to mice
transplanted with MC38 (mouse) or HT-29 human colon
cancer induced a tumor growth inhibition significantly greater
than tacalcitol alone and a significant prolongation of the
survival time of mice (Milczarek et al., 2013b,c). Another
study carried out on different cell lines, namely A549 (lung
cancer), B16 (murine melanoma), HL-60 (human leukemia),
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SW707 (human colon cancer), MCF-7 and T47D (breast
cancer), WEHI-3 (murine leukemia), and on normal murine
fibroblasts BALB-3T3 cells, demonstrated that the adminis-
tration of tacalcitol in association with cisplatin or doxorubi-
cin resulted in a significant decrease in the IC50 values of
these antitumor agents (Pelczynska et al., 2006). Furthermore,
Switalska et al. (2012) recently reported that the administra-
tion of tacalcitol enhanced the antiproliferative activity of
imatinib demesilate on HL-60 leukemia cells. Eldecalcitol
(1a, 25-dihydroxy-2b-[3-hydroxypropyloxy] vitamin D3),
(ED-71), is an orally administered analogue of active Vit D
that is mainly used in the clinical treatment of osteoporosis
(Sanford & McCormack, 2011) (Figure 2). Further experi-
mental studies showed that ED-71 is endowed with
chemopreventive activity against tumors and with reduced
hypercalcemic effects (Hatakeyama et al., 2010). Studies on
myeloid leukemia demonstrated the ability of this molecule to
induce tumor cells to differentiate into normal monocyte-
macrophages (Gocek & Studzinski, 2009; Hatakeyama et al.,
2010; Nishii & Okano, 2001). This molecule also inhibited
the proliferation of U937 human, histiocytic lymphoma cells,
and increased osteocalcin concentrations in the human
osteosarcoma cells (MG-63) (Hatakeyama et al., 2010).
Eldecalcitol is a CYP24A1-resistant analogue (Ritter &
Brown, 2011). CYP24A1 is expressed in many tissues and
cells, including the prostate, and appear to be implicated in
the resistance of prostate cancer to Vit D (Tannour-Louet,
2014). Therefore, ED-71 may be of clinical usefulness in the
prevention and treatment of prostate cancer (Chen et al.,
2012; Sakaki et al., 2014).
BXL 0124
BXL0124, a new analogue of Vit D, belongs to the deuterated
Gemini Vit D compounds (Figure 2). These compounds have
a C-20 methyl group, a deuterium-substituted side chain, and
a second side chain that has a double or triple bond and a
fluorine. BXL0124 has been shown to possess a chemo-
preventive effect on breast cancer and prostate cancer (Lee
et al., 2008; Spina et al., 2007; Wahler et al., 2014).
Interestingly, in vitro studies on MCF10DCIS cells showed
that this molecule had antiproliferative effects on breast
cancer and markedly decreased the expression of CD44 (So
et al., 2011). Intriguingly, recent observations showed that
BXL0124 inhibited breast cancer cell invasion by targeting
CD44-STAT3 signaling (So et al., 2013a). These findings are
consistent with the observations that the JAK2/STAT3
signaling pathway is essential for growth of the CD44+/
CD24 stem cell-like breast (Marotta et al., 2011). In
contrast, the inhibiting activity of this molecule on tumor
growth observed in vitro was further confirmed by in vivo
studies showing that either the oral (0.03 or 0.1 mg/kg) or
intraperitoneal (0.1mg/kg) administration of Gemini 6 d a
week for 5 weeks to mice-bearing tumor caused a reduction in
the growth of breast cancer and a consistent decrease in the
expression of CD44 protein, without causing hypercalcemia
(So et al., 2011). Consistent with these findings, Wahler et al.
(2014) showed that, in mice inoculated with ductal carcinoma
in situ (DCIS) MCF10DCIS com. cells, the administration of
BXL0124 resulted in a 43% reduction in tumor volume.
Moreover, BXL0124 treatment also decreased the mRNA
levels of MMPs starting at week 3, thus contributing to the
inhibition of invasive transition. These findings indicate that
this molecule may be an important target for the chemopre-
vention and treatment of breast cancer. Consistent with these
findings, a more recent study by So et al. (2013b) reported
that BXL0124 may be effective, in combination with other
molecules, as potential chemopreventive agent, but not for the
treatment, against the tumorigenesis of ErbB2-overexpressing
breast cancer. The same authors highlighted the fact that
BXL0124 (10 nM) induced expression of mRNA coding for
osteopontin, one of the genes regulated by Vit D, thus
contributing to the regulation of cell proliferation (So et al.,
2011). BXL0124 has also been shown to reduce tumor growth
by 50% and to prevent metastasis formation in the MC-26
colon cancer xenograft model while no effect was noted on
calcium homeostasis (Spina et al., 2007). These data warrant
future clinical studies to assess the pharmacological profile of
this analog in humans.
19-nor-1a,25(OH)2D3 analogs: MART-10, MART-11,
paracalcitol, and inecalcitol
MART-10 MART-11
19-nor-Vit D compounds are Vit D analogs in which the ring
A methylene group on C-19 is replaced with two hydrogen
atoms (Chen & Kittaka, 2011) (Figure 2). MART-10 (19-nor-
2a-(3-hydroxypropyl)-1a,25(OH)2D3) and MART-11 (19-
nor-2b-3-hydroxypropyl-1a,25(OH)2D3) are two new syn-
thetic C2-substituted 19-nor-1a,25(OH)2D3 analogs of Vit D
that have negligible effects on calcium plasma levels and that
appear to be effective in the prevention and treatment of
prostate cancer (Chen & Kittaka, 2011; Kittaka et al., 2012).
In vitro studies on the HL-60 cell line showed that compared
with 1,25(OH)2D3, MART-10, and MART-11 are endowed
with a different degree of binding affinity for VDR (100 and
3%). In addition, both analogues were more effective in
inducing cell differentiation, compared with 1,25(OH)2D3
(Arai & Kittaka, 2006; Ono et al., 2003). The discrepancy
between the rate of VDR binding and differentiation activity
was explained, at least in part, by their remarkable ability to
recruit co-activators, such as hTIF-2 and HSRC-1 (Arai et al.,
2007). The antiproliferative activity of MART-10 and MART-
11 was investigated in LNCaP and PC3 human prostate
cancer cells (Chen et al., 2003; Flanagan et al., 2009). These
investigations have shown that both analogues possess
antiproliferative activity comparable with that of
1,25(OH)2D3. However, MART-10 proves about 1000-fold
more active than 1a,25(OH)2D3 in inhibiting LNCaP and PC-
3 prostate cancer cell proliferation (Chen & Kittaka, 2011;
Iglesias-Gato et al., 2011). Furthermore, in vitro studies
which compared the expression level of the enzyme
CYP24A1 in LNCaP and PC-3 in response to treatment
with 1,25(OH)2D3 and MART-10 showed that this latter
molecule was able to induce the expression of CYP24A1, one
of the three major enzymes involved in the metabolism of Vit
D (Jones et al., 2012), to a lower concentration than calcitriol
(Flanagan et al., 2009). In vivo, the subcutaneous adminis-
tration of MART-10 was reported to up-regulate CYP24A1
mRNA expression in rat kidneys without affecting their
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plasma calcium levels (Iglesias-Gato et al., 2011). These
findings demonstrated that MART-10 is biologically active
in vivo and may be of clinical usefulness in treating prostate
cancer. Therefore, the induction of the CYP24A1 gene was
used as an index for evaluating the biological potency of new
Vit D analogs (Chen & Kittaka, 2011). These studies
additionally highlighted the fact that MART-10 induced
CYP24A1 gene expression at a lower concentration with a
longer duration compared with 1a,25(OH)2D3, suggesting that
MART-10 is less susceptible to CYP24A1 degradation
(Flanagan et al., 2009; Iglesias-Gato et al., 2011).
Furthermore, the effects induced by MART-10 lasted for a
longer period of time. This phenomenon indicated a low
susceptibility of this molecule to being degraded by
CYP24A1 (Flanagan et al., 2009). Interestingly, MART-10
has been shown to be a potent inhibitor of cancer cell
invasiveness (Chen & Kittaka, 2011). In fact, in vitro studies
on PC-3 prostate cancer cells showed that MART-10
determined down-regulation of matrix metalloproteinase-9
(MMP-9), an enzyme which fosters tumor invasion, angio-
genesis, and metastasis (Chen & Kittaka, 2011). More recent
observations by Chiang et al. (2014) show that MART-10 is
more active than 1a,25(OH)2D3 in preventing MCF-7 cell
invasion and migration, probably mediated through the up-
regulation of E-cadherin, and that of the transcription factors
implicated in epithelial–mesenchymal transition (EMT)
down-regulation, e.g., Snail, Slug, and Twist, as well as
MMP-13. These data further confirm and extend previous
finding of the same authors showing that MART-10 is also
able to inhibit cell proliferation and to induce apoptosis in
MCF-7/ER(+) breast cancer cells (Chiang et al., 2012). These
findings suggest that these analogues and their structurally
related analogues may be good candidates for the treatment of
different human tumors including breast, prostate, and liver
cancers (Kittaka et al., 2012). These observations warrant
further in vivo animal study to better assess the pharmaco-
logical profile and the therapeutic effectiveness of these
molecules in humans.
Paricalcitol
Paricalcitol (19-nor-1a,25-dihydroxyvitamin D2) is a syn-
thetic analog of calcitriol, the active form of Vit D (Figure 2).
Experimental in vitro and in vivo studies have reported that
paricalcitol presents anticancer activity against several hema-
tological and solid tumors including myeloid leukemia,
myeloma, gastric cancer, colon cancer, and pancreatic
cancer and that these effects may be mediated through the
VDR (Kumagai et al., 2003, 2005; Park et al., 2012; Schwartz
et al., 2005, 2008). Interestingly, recent clinical observation
by Lawrence et al. (2013) has shown that paricalcitol, in
combination with taxane-based chemotherapy, appears to be
safe and feasible and may have a clinical benefit for women
with metastatic breast cancer. Unlike these findings, Schwartz
et al. (2005) did not observe any clear response in patients
with advanced prostate cancer. On the other hand, in HL-60
and NB4 myeloid leukemia cell lines, paricalcitol was noted
to suppress proliferation and induce differentiation (Kumagai
et al., 2005; Molnar et al., 2004). In human NCI-H929
myeloma cells, this molecule inhibited cell growth by causing
cell-cycle block and apoptosis indicating its potential as an
antileukemic agent (Molnar et al., 2004). Furthermore, in
patients with all-trans-retinoic acid (ATRA)-resistant myeloid
leukemia a combination therapy consisting of paricalcitol and
arsenic trioxide also appears to be promising (Kumagai et al.,
2005). These findings together with its low calcemic activity
and achievable therapeutic doses strongly support its use in
clinical trials regarding hematological diseases such as MDS
and acute myeloid leukemia.
Inecalcitol
Inecalcitol is a novel Vit D 19-nor analogue (19-nor-14-epi-
23-yne-1,25 dihydroxyvitamin D3) that differs from
1,25(OH)2D3 through epimerization of C14, deletion of
C19, and 23-yne modification in the side chain (Figure 2)
(Verlinden et al., 2000). This analogue appears to be less
inclined to induce hypercalcemia while it remains a potent
stimulant of VDR (Verlinden et al., 2000). Inecalcitol has
been shown to suppress both in vitro and in vivo the growth of
human LNCaP prostate cancer and that of SCC (Ma et al.,
2013a,b; Okamoto et al., 2012). The antitumor activity of
inecalcitol, at least in SCC, appears to be the consequence of
(a) the arrest of tumor cells in G0/G1 transition phase of the
cell cycle, (b) the triggering of the apoptosis cascade through
the activation of caspase 8/10–caspase 3 pathway, and (c) the
inhibition of expression of c-IAP1 and XIAP. Inecalcitol has
also been shown to repress cyclin D1 and cyclin C gene
expression and to induce p21 and p27 gene expression more
efficiently than calcitriol (Ma et al., 2013a). Inecalcitol has
been utilized in clinical studies in association with the
classical antitumor agent docetaxel (Medioni et al., 2014).
The results of the phase II trial in castration-resistant prostate
cancer showed that this drug combination had a better PSA
response than docetaxel alone. These data provide support for
further evaluation of inecalcitol in cancer treatment.
Conclusions
On one hand, epidemiological observations highlight the fact
that high levels of vitamin D may offer protection against
many types of cancer (Leyssens et al., 2013; Pilz et al., 2013).
On the other hand, many experimental studies provide
evidence for the growth inhibiting, anti-inflammatory, and
pro-differentiation effects of Vit D in vitro on human cancer
cell lines and in vivo on tumor-bearing animals (Krishnan &
Feldman, 2011; Meeker et al., 2014; Trump et al., 2010;
Vanoirbeek et al., 2011). Therefore, the use of vitamin D or its
semisynthetic analogues in cancer therapy could provide
effective chemopreventive effects against tumor progression
(Byers et al., 2012; Krishnan & Feldman, 2011; Meeker et al.,
2014; Trump et al., 2010; Vanoirbeek et al., 2011). The
possible mechanisms by which vitamin D mediates these
effects have been, only in part, identified. Although the
preclinical data are striking and the epidemiologic data are
encouraging, no well-designed clinical trial on the optimal
administration of vitamin D as a cancer therapy has ever been
undertaken (Krishnan & Feldman, 2010; Leyssens et al.,
2014). Future clinical investigations may better define the
clinical role of Vit D or its analogues in cancer prevention and
treatment. Another relevant feature of the paradigm Vit D/
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cancer needing further investigation is related to tumor
resistance as this phenomenon may affect the synthesis of the
active metabolite of Vit D and, consequently, its potential
therapeutic activity (Ajibade et al., 2014; Giardina et al.,
2012; Larriba & Mun˜oz, 2010; Tannour-Louet, 2014).
Therefore, many studies are currently directed to find new
molecules which may circumvent tumor resistance to Vit D
analogues (Deeb et al., 2007; Fischer et al., 2012; Ritter &
Brown, 2011; Solomon et al., 2014).
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